Antibody-drug conjugates

CN122742898APending Publication Date: 2026-09-11北京昭衍生物技术有限公司
View PDF 54 Cites 0 Cited by

Patent Information

Application Number
CN202580010642.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-18
Filing Date
2025-01-20
Publication Date
2026-09-11

Smart Images

  • Figure CN122742898A_ABST
    Figure CN122742898A_ABST
Patent Text Reader

Abstract

An antibody-drug conjugate (ADC) is provided, comprising an anti-TROP2 antibody and an antitumor compound linked by a linker, wherein the linker and the antitumor compound are represented by the general formula -Q-L1-L2-(NH-Exa). This ADC can be used as a therapeutic agent, particularly suitable for cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] sequence list

[0002] The contents of the following sequence listing are incorporated herein by reference in their entirety: Text name: ADCSEQLIST2.xml, Date of record: 2023.12.25, Size: 23KB. Technical Field

[0003] This application relates to an antibody-drug conjugate (ADC) comprising one or more antitumor drug portions, the drug portions being conjugated to an anti-TROP2 antibody or an antigen-binding portion via a linker, as well as methods of manufacturing the ADC and its uses, including methods of treating cancer. Background Technology

[0004] Antibody-drug conjugates (ADCs), as a novel type of targeted drug, typically consist of three parts: an antibody or antibody-like ligand, one or more cytotoxic drugs, and a linker that conjugates the drug to the antibody.

[0005] Antibody-adjuvant drugs (ADCs) can target and deliver cytotoxic drugs, particularly to cancer cells, which can reduce the side effects commonly associated with chemotherapy. The antibody portion of an ADC binds to antigens expressed on the surface of cancer cells and can induce internalization within the cells, selectively delivering the drug to cancer cells. Therefore, it is expected that this will lead to drug accumulation within cancer cells and the killing of those cells. Drug molecules are typically linked to amino acid residues (such as cysteine ​​or lysine) on the antibody molecule via cleavable or non-cleavable linkers.

[0006] Trop-2 (human trophoblast cell surface marker) is a cell surface glycoprotein initially discovered in normal and malignant trophoblast cells (Lipinski et al., 1981, Proc Natl. Acad Sci USA 78:5147-50). Trop-2 is highly expressed in most human cancers, particularly epithelial and adenocarcinomas, and has been reported to be expressed at low or restricted levels in normal tissues (see, e.g., Cubas et al., 2010, Molec Cancer 9:253; Stepan et al., 2011, J Histochem Cytochem 59:701-10; Varughese et al., 2011, Am J Obst Gyn 205:567e-e7). Trop-2 expression is associated with metastasis, increased tumor invasiveness, and shortened patient survival. It has been reported that the pathogenicity of Trop-2 is mediated at least in part by the ERK 1 / 2MAPK pathway (Cubas et al., 2010).

[0007] Trop-2 is overexpressed in many different types of human cancers, including adenocarcinoma and squamous cell carcinoma, and its transmembrane localization properties make it a potential target for anticancer immunotherapy. There is an urgent need to develop effective antibody-drug conjugates (ADCs) targeting Trop-2 as a treatment for Trop-2-positive cancers.

[0008] Topoisomerase I (TOPO I) inhibitors represent the latest breakthrough in ADC payload innovation, with the approval of two ADCs containing camptothecin (CPT) analogs: Trastuzumab deruxtecan (DS-8201a—Enhertu®) and sacituzumab govitecan (IMMU-132—Trodelvy®). Despite this breakthrough, DXd and SN-38 ADCs still face intrinsic and acquired resistance due to tumor heterogeneity and multidrug resistance (MDR) modulation (Garcia-Alonso S, Ocana A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res 2018;78:2159–65; Collins DM et al., Acquired resistance to antibody-drug conjugates. Cancers (Basel) 2019;11:394).

[0009] Exatecan is a camptothecin derivative and a precursor to DXd. Due to its high TOP1 inhibitory potency (Joto N et al., DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer 1997;72:680-6; Jo U et al., TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor. MolCancer Ther 2022;21:1090–102.), decreased sensitivity to ABCG2 or P-gp (van Hattum AH et al., Induction of breast cancer resistance protein by the camptothecinderivative DX-8951f is associated with minor reduction of antitumor activity. Br J Cancer 2002;87:665-72), and higher permeability and bystander permeability (Khera E, Dong S, Huang H, de Bever L, van Delft FL, Thurber GM. Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates. MolCancer Ther 2022;21:310–21) attracted initial attention.

[0010] Exatecan is the most potent drug, inducing TOP1ccs at lower concentrations than Dxd and SN-38. However, exatecan is too hydrophobic to be directly conjugated to antibodies (Ogitani Y et al., Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorg Med Chem Lett 2016; 26:5069-72). While this active ingredient shows promising potential, its application as an ADC payload is limited by its hydrophobicity and challenging biophysical properties, which appear to be primarily due to steric hindrance surrounding the stereodefined primary amine (Nakada, T et al., Novel Antibody Drug Conjugates Containing Exatecan Derivative-Based Cytotoxic Payloads. Bioorg. Med. Chem. Lett. 2016, 26, 1542-1545).

[0011] Recently, ecetane has also been considered as a payload for antibody-drug conjugates (ADCs), and various linker forms have been screened, as reported by Nakada et al., Bioorg. Med. Chem. Lett. 2016, 26, 1542-1545, which is incorporated herein by reference. However, observations revealed that exatecan-based ADCs exhibited extensive aggregation, up to 26%.

[0012] Therefore, it is both necessary and urgent to find a more effective antibody-drug conjugate to treat cancer.

[0013] All publications, patents, patent applications, and disclosures of published patent applications mentioned in this article are included herein for informational purposes.

[0014] Application Overview

[0015] One aspect of this application provides an antibody-drug conjugate comprising an anti-TROP2 antibody and an antitumor compound linked by a linker, wherein the linker and the antitumor compound are represented by the general formula -Q-L1-L2-(NH-Exa), wherein,

[0016] Q is -(succinimide-3-yl-N)-(CH2)5-C(═O)-,

[0017] Wherein, -(succinimide-3-yl-N)- is a group represented by the following structure:

[0018] ,

[0019] This group is linked to the antibody at position 3 and to a methylene group on the nitrogen atom at position 1.

[0020] L1 is a dipeptide with the structural formula -Val-Cit-.

[0021] L2 is -NH-phenyl-CH2-OC(═O)- and has the following structure:

[0022] ,

[0023] -(NH-Exa) is a group represented by the following structure:

[0024] .

[0025] In some preferred embodiments, this application provides an antibody-drug conjugate comprising an anti-TROP2 antibody and an antitumor compound linked by a linker, wherein the linker and the antitumor compound have the following structure: -(succinimide-3-yl-N)-CH2CH2CH2CH2CH2-C(═O)-Val-Cit-NH-phenyl-CH2-OC(═O)-(NH-Exa)

[0026] in,

[0027] -(succinimide-3-yl-N)- is a group represented by the following structure:

[0028]

[0029] This group is linked to the antibody at position 3 and to a methylene group on the nitrogen atom at position 1.

[0030] -(NH-Exa) is a group represented by the following structure:

[0031]

[0032] The amino group at position 1 is the linking position, and

[0033] -NH-phenyl-CH2-OC(═O)- represents the following structure:

[0034] .

[0035] In some embodiments, the anti-TROP2 antibody is selected from Sacituzumab or Datopotamab.

[0036] Compositions, kits, and products containing any of the above-mentioned antibody-drug conjugates are also provided.

[0037] Brief description of the attached figures

[0038] Figures 1A and 1B show the in vivo results of the antitumor efficacy test of ADC in a mouse model of MDA-MB-468 cancer cells. Figure 1A shows the change in tumor volume over time in each group. Figure 1B shows the curve of mouse body weight change.

[0039] Figures 2A and 2B show the in vivo results of the antitumor efficacy test of ADC in a mouse model of HCC1806 cancer cells. Figure 2A shows the change in tumor volume over time in each group. Figure 2B shows the curve of mouse body weight change.

[0040] Detailed description

[0041] This application provides an antibody-drug conjugate comprising an anti-TROP2 antibody and an antitumor compound or eczema toxin linked by a linker.

[0042] definition

[0043] As described in this application, the term "antibody" is broad and includes various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (such as bispecific antibodies), full-length antibodies, and their antigen-binding fragments, as long as they exhibit the desired antigen-binding activity. In some embodiments, a full-length antibody comprises two heavy chains and two light chains. Variable regions of the light and heavy chains are responsible for antigen binding. The variable regions in both chains typically include three hypervariable loops, referred to as complementarity-determining regions (CDRs). Light chain (LC) CDRs include LC-CDR1, LC-CDR2, and LC-CDR3, and heavy chain (HC) CDRs include HC-CDR1, HC-CDR2, and HC-CDR3. The CDR boundaries of the antibody or antigen-binding fragments disclosed in this application can be defined or identified according to the Kabat, Chothia, or Al-Lazikani conventions (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). Three CDR regions of the heavy or light chain are inserted between flanking segments called framework regions (FRs), which are more conserved than the CDR regions and form a scaffold supporting the hypervariable loop. The constant regions of the heavy and light chains do not participate in antigen binding but exhibit various effector functions. Antibodies are classified based on the amino acid sequence of their heavy chain constant regions. The five main classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, characterized by having α, δ, ε, γ, and μ-type heavy chains, respectively. Several major antibody classes are divided into subclasses, such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain n) or IgA2 (α2 heavy chain).

[0044] The antibody in this application can be any antibody capable of targeting tumor cells. That is, after being linked to a drug with anti-tumor activity via a linker, the antibody preferably has one or more of the following properties: the ability to recognize tumor cells, the ability to bind to tumor cells, the ability to internalize into tumor cells, and the ability to damage tumor cells.

[0045] As described in this application, the term "antigen-binding fragment" includes an antibody fragment, including, for example, a double-chain antibody (diabody), Fab, Fab', F(ab')2, Fv fragment, disulfide-stabilized Fv fragment (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized double-chain antibody (ds double-chain antibody), single-chain antibody (scFv), scFv dimer (bivalent double-chain antibody), multispecific antibody composed of antibody fragments containing one or more CDRs, single-domain antibody, nanobody, domain antibody, bivalent domain antibody, or any other antibody fragment capable of binding to an antigen but not containing a complete antibody structure. Wherein, Fab (fragment antigen-binding) as described in this application is a V containing an antibody. L Structural domain, V H Domain, C L Domain, and C H A monovalent fragment of a 1-domain structure. The antigen-binding fragment also includes a fusion protein comprising the antibody fragment described above. The antigen-binding fragment is capable of binding the same antigen to a parent antibody or a parent antibody fragment (such as a parental scFv). In some embodiments, the antigen-binding fragment may include one or more CDRs from a specific human antibody that are grafted into the frame region from one or more different human antibodies.

[0046] As described in this application, an “isolated” antibody means an antibody that (1) is not related to a naturally occurring protein, (2) does not contain other proteins of the same origin, (3) is expressed by cells of a different species, or (4) does not exist in nature.

[0047] As described in this application, the term "isolated nucleic acid" means a nucleic acid or combination thereof of genomic, cDNA, or synthetic origin. Depending on its origin, the "isolated nucleic acid" (1) is not related to all or part of the polynucleotides in "isolated nucleic acids" found in nature, (2) can be operatively linked to polynucleotides not naturally associated with it, or (3) does not exist in nature as part of a longer sequence.

[0048] As described in this application, the term "CDR" or "complementarity-determining region" refers to a discontinuous antigen-binding site found within the variable region of a heavy-chain or light-chain polypeptide. In the literature Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat et al., US Dept. of Health and Human Services, “Sequences of proteins of immunological interest” (1991); Chothia et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. et al., J. Mol. Biol., 273: 927-948 (1997); MacCallumet al., J. Mol. Biol. 262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Lefranc MP et al., Dev. Comp. Immunol., 27:55-77 (2003); These specific regions have been described in Honegger and Plückthun, J. Mol. Biol., 309:657-670 (2001), where these definitions include overlaps or subsets of amino acid residues when compared with each other. However, any definition used to indicate a CDR of an antibody or transplanted antibody or its variant is included within the scope of the terminology defined and used in this application. Table 1 lists the positions of the amino acid residues included in the CDRs defined by the aforementioned references for comparison. Algorithms and interfaces for CDR prediction are known in the art, including, for example, those described in Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Ehrenmann F. et al., Nucleic Acids Res., 38: D301-D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43: D432-D438 (2015). The entire contents of the references cited in this paragraph are incorporated herein by reference for use in this application and in one or more claims that may be included herein. CDR numbering in this application follows Kabat's naming conventions.

[0049] Table 1: CDR Definition

[0050]

[0051] 1 The amino acid residue numbering is as described above in Kabat. et al. Naming methods in

[0052] 2 The amino acid residue numbering refers to the above Chothia et al. Naming methods in

[0053] 3 The amino acid residue numbering refers to the above MacCallum et al. Naming methods in

[0054] 4 The amino acid residue numbering is as described above for Lefranc. et al. Naming methods in

[0055] 5 The amino acid residue numbering follows the nomenclature method described in Honegger and Plückthun.

[0056] The term "chimeric antibody" refers to an antibody whose heavy chain and / or light chain portion is identical or homologous to the corresponding sequence in an antibody from a particular species or belonging to a particular antibody species or subclass, while the remaining portion of this chain is identical or homologous to the corresponding sequence in an antibody from another genus or belonging to another antibody species or subclass, as well as fragments of such antibodies, provided they possess the biological activity described in this application (see US Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

[0057] The “humanized” form of non-human (e.g., rodent) antibodies is a chimeric antibody, which includes a minimal sequence derived from the non-human antibody. In most cases, humanized antibodies are human immunoglobulins (receptor antibodies), where the hypervariable region (HVR) residues of the receptor antibody are replaced by hypervariable region residues from non-human species such as mice, rats, rabbits, or non-human primates (donor antibodies) that possess desirable antibody specificity, affinity, and performance. In some cases, residues in the human immunoglobulin framework region (FR) are replaced by corresponding non-human residues. Additionally, humanized antibodies may include residues not present in either the receptor or donor antibody. These modifications can further improve antibody performance. Typically, humanized antibodies contain substantially at least one, usually two, variable regions, where all or substantially all of the hypervariable loops correspond to the hypervariable loops of a non-human immunoglobulin, and all or substantially all of the framework regions are human immunoglobulin sequences. Humanized antibodies may also optionally include at least a portion of the immunoglobulin constant region (Fc), typically the constant region of a human immunoglobulin. For details, please refer to Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[0058] The "percentage of amino acid sequence homology (%)" or "homology" of the peptide and antibody sequences identified in this application is defined as: the percentage of identical amino acid residues in a candidate sequence compared to a peptide sequence, assuming that conserved substitutions are part of sequence homology. The percentage of amino acid sequence homology can be determined using various alignment methods within the scope of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. Those skilled in the art can determine suitable parameters for measuring alignment, including any algorithm required to maximize alignment across the full length of the compared sequences. However, for the purposes of this application, the percentage of amino acid sequence homology is a numerical value obtained using the sequence alignment computer program MUSCLE (Edgar, RC, Nucleic Acids Research 32(5):1792-1797, 2004; Edgar, R.C., BMC Bioinformatics Generated from 5(1):113, 2004).

[0059] Unless otherwise stated, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate forms of each other and encode the same amino acid sequence. Nucleotide sequences encoding proteins or RNA may also include introns; for example, nucleotide sequences encoding proteins may contain introns in certain forms.

[0060] The term "operationally ligated" refers to a functional link between a regulatory sequence and a heterologous nucleotide sequence, thereby enabling the latter to be expressed. For example, the first and second nucleotide sequences are operably ligated when they are in a functional relationship. Similarly, if a promoter affects the transcription or expression of a coding sequence, the promoter and coding sequence are operably ligated. Typically, operably ligated DNA sequences are contiguous, and, if necessary, two protein-coding regions can be ligated within the same reading frame.

[0061] As described in this application, "treatment" or "treating" is a method of obtaining a beneficial or desired outcome, including clinical outcomes. For the purposes of this application, the beneficial or desired clinical outcomes include, but are not limited to, one or more of the following: relieving one or more symptoms caused by a disease, reducing the severity of the disease, stabilizing the disease (e.g., preventing or delaying disease progression), preventing or delaying the spread of the disease (e.g., metastasis), preventing or delaying disease recurrence, delaying or slowing disease progression, improving the disease state, alleviating the disease (partially or completely), reducing the dosage of one or more other medications required to treat the disease, delaying disease progression, improving or enhancing quality of life, gaining weight, and / or prolonging survival. "Treatment" also includes a reduction in disease pathological outcomes (e.g., tumor volume in cancer). The methods of this application consider any one or more aspects of these treatments.

[0062] The “effective amount” of the antibody or composition disclosed in this application refers to an amount sufficient to achieve a specific purpose. The “effective amount” can be determined empirically and by known methods associated with said purpose.

[0063] The term "therapeutic effective amount" refers to the amount of antibody, ADC, or composition described in this application that is effective in "treating" an individual's disease or condition. In the case of cancer, a therapeutically effective amount of the antibody, ADC, or composition disclosed in this application may reduce the number of cancer cells; reduce tumor size or weight; inhibit (i.e., to some extent slow down and preferably stop) the infiltration of tumor cells into peripheral cells; inhibit (i.e., to some extent slow down and preferably stop) tumor metastasis; inhibit tumor growth to some extent; and / or alleviate one or more symptoms associated with cancer to some extent. If the antibody, ADC, or composition of this application is able to prevent cancer cell growth and / or kill existing cancer cells, it may have cytoseptic and / or cytotoxic properties. In some embodiments, a therapeutically effective amount is an amount that inhibits growth. In some embodiments, a therapeutically effective amount is an amount that prolongs patient survival. In some embodiments, a therapeutically effective amount is an amount that improves patient progression-free survival.

[0064] As used in this application, "pharmaceutical acceptable" or "pharmacologically compatible" means a material that has no biological activity or other undesirable properties, such as the ability to be incorporated into a pharmaceutical composition given to a patient without causing significant adverse biological reactions, or that does not interact harmfully with any other components contained in the composition. Pharmaceutically acceptable carriers or excipients preferably meet the required standards for toxicological or manufacturing testing and / or are included in the inactive ingredient guidelines prepared by the U.S. Food and Drug Administration.

[0065] The antitumor compounds disclosed in this application (also referred to herein as "toxins") may include one or more asymmetric centers and may exist in different diastereomers and / or enantiomers. Unless otherwise stated, the description of any compound in this application is intended to include all diastereomers and mixtures thereof. Furthermore, unless otherwise stated, the description of any compound in this specification and claims is intended to include enantiomers and any mixtures, racemates, or other forms of enantiomers. When the structure of a compound is described as a particular enantiomer, it should be understood that this application is not limited to that particular enantiomer.

[0066] Compounds or toxins can exist in various tautomer forms. Unless otherwise stated, compounds according to this application are intended to include all tautomer forms. When the structure of a compound is described as a particular tautomer, it should be understood that the application of this application is not limited to that particular tautomer.

[0067] The compounds disclosed in this specification and claims may also exist as R and S stereoisomers. Unless otherwise stated, the description of any compound in the specification and claims is intended to include the individual R and S stereoisomers of the compound, as well as mixtures thereof. When the structure of a compound is described as a particular S or R stereoisomer, it should be understood that the application of this application is not limited to that particular S or R stereoisomer.

[0068] The compounds disclosed in this specification and claims may also exist as exo- and endo-diastereomers. Unless otherwise stated, the description of any compound in the specification and claims is intended to include individual exo- and endo-diastereomers of the compound, as well as mixtures thereof. When the structure of a compound is described as a particular endo- or exo-diastereomer, it should be understood that the application of this application is not limited to that particular endo- or exo-diastereomer.

[0069] The compounds according to this application may exist in the form of salts, which are also covered by this application. Such salts are generally pharmaceutically acceptable salts containing pharmaceutically acceptable anions. The term "salt" refers to a compound formed when an acidic proton (usually a proton of an acid) is replaced by a cation (e.g., a metal cation or an organic cation). Where applicable, the salt is pharmaceutically acceptable, but this requirement is not necessary for salts not intended for patient administration. For example, in a salt of a compound, the compound may be protonated by an inorganic or organic acid to form a cation, wherein the conjugate base of the inorganic or organic acid serves as the anionic component of the salt.

[0070] The term "half-maximal effective concentration (E50)" refers to the concentration of a drug, antibody, or toxicant that elicits half the response between the baseline and the maximum response after a certain exposure time. It is commonly used as a measure of drug efficacy. Therefore, the EC50 of a gradient dose-response curve represents the concentration of the compound at which 50% of its maximum effect is observed. The EC50 of a quantitative dose-response curve represents the concentration of the compound at which 50% of the population exhibits a response after a specified exposure duration. Concentration measurements typically follow an S-shaped curve, increasing rapidly at relatively small concentration changes. This can be mathematically calculated by deriving a best-fit line.

[0071] In some embodiments, the EC50 defined in this application characterizes the potency of the antibody to bind to a target on human tumor cells. The EC50 parameter is determined using FACS analysis. The EC50 parameter reflects the antibody concentration such that the maximum binding rate to the human target expressed on tumor cells reaches 50%. Each EC50 value is obtained by calculating the midpoint of the dose-response curve using a four-parameter regression curve fitting procedure (Prism software). This parameter has been selected to represent a physiological / pathological condition.

[0072] The term "half-maximal inhibitory concentration (IC50)" is an indicator of the potency of a substance in inhibiting a specific biological or biochemical function. IC50 is a quantitative indicator that represents the amount of a specific inhibitor (e.g., a toxin) required to inhibit a given biological process or component by 50% in vitro. IC50 values ​​are usually expressed as molar concentration.

[0073] The embodiments of this application described herein should be understood to include embodiments that are “composed of” and / or “substantially composed of”.

[0074] References to the “about” value or parameter here include (and describe) variations that refer to the value or parameter itself. For example, a description of “about X” includes a description of “X”.

[0075] As used in this application, the reference to "not" a numerical value or parameter generally indicates and describes something other than a certain numerical value or parameter. For example, the statement that the method cannot be used to treat type X cancer means that the method is generally used to treat other types of cancer besides type X cancer.

[0076] Unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the” used in this application and the claims include plural objects.

[0077] Antibody

[0078] The antibodies used in the antibody-drug conjugates of this application refer to molecules containing an antigen-binding domain that specifically binds to an antigen. The antibodies of this invention can be any of IgG, IgE, IgM, IgD, IgA, and IgY (classes), but IgG is a preferred subclass. Subclasses can be any of IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, with IgG1 and IgG2 being preferred. Antibodies can be derived from any species, but human, rat, mouse, and rabbit are preferred. When derived from species other than humans, it is preferred to use known techniques to chimeric or humanize them. The antibodies of this invention can be polyclonal or monoclonal antibodies, but monoclonal antibodies are preferred.

[0079] The antibody in this application can be any antibody capable of targeting tumor cells. That is, after a drug with anti-tumor activity (e.g., a toxin) is linked to the antibody via a linker, the antibody preferably has one or more of the following properties: the ability to recognize tumor cells, the ability to bind to tumor cells, the ability to internalize into tumor cells, and the ability to damage tumor cells.

[0080] This application includes antibodies that exhibit high internalization capacity upon binding to a target. As used herein, an "internalizing" or "internalizing" antibody (both with similar expressions) is an antibody that is absorbed (meaning "entered") by mammalian cells after binding to a target on a cell. This antibody is an important component of an ADC (antibody-drug conjugate) that can localize (target) attached cytotoxic drugs to target cancer cells. Once the cytotoxic drug is internalized by the cell, it triggers cancer cell death.

[0081] Ideally, the antibody itself should have anti-tumor effects, but this is not essential. For the antibody to exert its anti-tumor effect and for the drug to specifically and selectively destroy tumor cells, the ability to internalize and migrate into tumor cells is important and, more preferably, desirable. The key to successful ADC therapy is considered to be target antigen specificity and the internalization of the antigen-antibody complex within cancer cells. Clearly, internalized antigens deliver cytotoxic drugs more effectively than uninternalized antigens. The process of antigen internalization varies and depends on a number of parameters that can be influenced by the antibody.

[0082] Flow cytometry can be used to confirm the binding activity of antibodies to tumor cells. Antibody entry into tumor cells can be confirmed by the following methods: (1) using fluorescence microscopy to examine the antibodies entering the cells with a secondary antibody (fluorescent label) bound to a therapeutic antibody (Cell Death and Differentiation (2008) 15, 751-761); (2) using a secondary antibody (fluorescent label) bound to a therapeutic antibody to measure the amount of fluorescence entering the cells (Molecular Biology of the Cell vol.15, 5268-5282, December 2004); or, (3) Mab-ZAP assay, in which an immunotoxin conjugated to a therapeutic antibody is used, which releases the toxin upon entering the cell, thereby inhibiting cell proliferation (BioTe chniques 28:162-165, January 2000).

[0083] In a preferred embodiment, the internalization of the antibody of this application can be assessed by immunofluorescence or FACS, as illustrated below, or by any method or process known to those skilled in the art, particularly regarding the internalization mechanism. In a preferred embodiment, the antibody of this application can induce at least 30%, preferably 50%, and more preferably 80% internalization upon binding to the target. In some embodiments, the efficiency of antibody-mediated internalization varies significantly depending on the targeted epitope. Selecting an effective internalizing antibody requires various experimental determinations, including studying not only target downregulation but also detecting antibody entry into cells.

[0084] The binding specificity of the antibody or its antigen-binding unit disclosed in this application can be determined by in vitro experiments, such as co-immunoprecipitation, radioimmunoassay (RIA), surface plasmon resonance, flow cytometry, or enzyme-linked immunosorbent assay (ELISA).

[0085] On one hand, this application provides antibody-drug conjugates comprising antibodies, wherein the antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibodies comprising the heavy chain and / or light chain CDRs discussed herein. Contemplated antibodies include, for example, full-length antibodies (e.g., full-length IgG1 or IgG4), scFvs, antibody Fc fusion proteins, multispecific (e.g., bispecific) antibodies, immunoconjugates, etc. In some embodiments, the antibody is Fab, aFab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragments, dAb, Fd, nanobodies, biantibodies, or linear antibodies. In some embodiments, reference to an antibody that specifically binds to a target means that the binding affinity of the antibody to the target is at least about 10 times higher (e.g., at least about 10, 10) than its binding affinity to a non-target. 2 , 10 3 , 10 4 , 10 5 , 10 6 , or 10 7 (Multiple times). Binding affinity can be determined by methods known in the art, such as ELISA, fluorescence activated cell sorting (FACS) analysis, or radioimmunoassay (RIA). Kd can be determined by methods known in the art, such as surface plasmon resonance (SPR) assay or biolayer interferometry (BLI).

[0086] While this document discusses antibodies containing human sequences (e.g., human heavy and light chain variable domains containing human CDR sequences), non-human antibodies are also considered. In some embodiments, a non-human antibody comprises the human CDR sequence and non-human frame region sequence of the antibody described herein. In some embodiments, the non-human frame region sequence comprises any sequence used to generate heavy and / or light chain variable domains using one or more human CDR sequences as described herein, including, for example, mammals such as mice, rats, rabbits, pigs, cattle (e.g., cows, bulls, buffalo), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (e.g., apes, macaques), etc. In some embodiments, a non-human antibody comprises an antibody generated by transplanting one or more human CDR sequences described herein into a non-human frame region (e.g., a mouse or chicken frame region sequence).

[0087] In some embodiments, the antibody cross-reacts with at least one allelic variant of its target protein (or a fragment thereof). In some embodiments, the allelic variant has up to 30 amino acid substitutions (e.g., conserved substitutions) compared to a naturally occurring target protein (or a fragment thereof).

[0088] In some embodiments, the amino acid substitutions described above are limited to the “Exemplary Substitutions” shown in Table A herein. In some embodiments, the amino acid substitutions are limited to the “Preferred Substitutions” shown in Table A herein.

[0089] In some embodiments, a competition assay can be used to identify monoclonal antibodies that competitively bind to the same target as the antibody described herein. A competition assay can determine whether two antibodies bind to the same epitope by identifying identical or spatially overlapping epitopes or by one antibody competitively inhibiting the binding of another antibody to the antigen. In some embodiments, such a competing antibody binds to the same epitope as the antibody described herein. Some exemplary competition assays include, but are not limited to, conventional assays as described in Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold SpringHarbor Laboratory, Cold Spring Harbor, NY). Detailed exemplary methods for resolving antibody-bound epitopes are described in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ). In some embodiments, if each antibody blocks 50% or more of the binding of another antibody, they are said to bind to the same epitope. In some embodiments, the antibody competing with the antibody described herein is a chimeric antibody, a humanized antibody, or a fully human antibody.

[0090] TROP2

[0091] TROP2 is a member of the TACSTD family and is expressed in human trophoblast cells. It is a single-transmembrane type 1 cell membrane protein that participates in immune resistance, a common feature of human trophoblast cells and cancer cells.

[0092] For the TROP2 protein used in this application, the TROP2 protein can be directly purified from TROP2-expressing cells of humans or non-human mammals (such as rats or mice), and cell membrane components of these cells can be prepared and used. Further, the TROP2 can be obtained through in vitro synthesis or through genetic engineering in host cells. Specifically, in genetic engineering, after integrating TROP2 cDNA into a vector capable of expressing TROP2 cDNA, the TROP2 protein can be obtained by synthesizing it in a solution containing the enzymes, substrates, and energy substances required for transcription and translation, or by expressing TROP2 in another prokaryotic or eukaryotic transformed host cell. Alternatively, the aforementioned genetically engineered TROP2-expressing cells or TROP2-expressing cell lines can be used as the TROP2 protein.

[0093] The DNA and amino acid sequences of TROP2 can be found in public databases and can be referenced, for example, by accession numbers NM_002353 and NP_002344 (NCBI).

[0094] In addition, TROP2 also contains a protein in which one or more amino acids are replaced, deleted, and / or added in its amino acid sequence, and this protein has biological activity equivalent to any of the amino acid sequences in TROP2.

[0095] The human TROP2 protein consists of a signal peptide sequence of 26 amino acid residues at the N-terminus, an extracellular domain of 248 amino acid residues, a transmembrane domain of 23 amino acid residues, and an intracellular domain of 26 amino acid residues.

[0096] In some embodiments, examples of cell lines expressing TROP2 may include human lung cancer cell lines NCI-H322, PC14, NCIH-H2122 and LCAM1, human prostate cancer cell line PC3, human pancreatic cancer cell lines BxPC-3, Capan-1 and PK-1, human ovarian cancer cell line SKOV3 and human colorectal cancer cell line COLO205.

[0097] Anti-TROP2 antibody

[0098] The anti-TROP2 antibody used in the anti-TROP2 antibody-drug conjugate of this application can be derived from any species, and preferred examples of such species include humans, rats, mice, and rabbits. When derived from species other than humans, chimerism or humanization using known techniques is preferred. The antibodies of this invention can be polyclonal or monoclonal antibodies, preferably monoclonal antibodies.

[0099] Anti-TROP2 antibodies can target tumor cells, meaning they have the ability to recognize tumor cells, bind to tumor cells, and enter tumor cells. Furthermore, they can be conjugated to compounds with anti-tumor activity through linkers, transforming them into antibody-drug conjugates.

[0100] In some embodiments, the anti-TROP2 antibody described herein has the following properties: (a) specifically binds to TROP2 and has the activity of being internalized in TROP2-expressing cells by binding to TROP2.

[0101] Anti-TROP2 antibodies can be obtained using methods conventional in the art, which involve immunizing animals with an antigenic peptide and collecting and purifying the antibodies produced in vivo. The source of the antigen is not limited to humans; antigens derived from non-human animals such as mice, rats, etc., can be used to immunize animals. In this case, the cross-reactivity of the obtained heterologous antigen-binding antibody with the human antigen can be tested to screen for antibodies suitable for human diseases.

[0102] Alternatively, antibody-producing cells that produce antibodies against the antigen can be fused with myeloma cells using methods known in the art (e.g., Kohler and Milstein, Nature (1975) 256, p. 495-497; and Kennet, R. ed., Monoclonal Antibodies, p. 365-367, Plenum Press, NY (1980)) to establish a hybridoma, from which monoclonal antibodies can be obtained.

[0103] Antigens can be obtained by genetically engineering host cells to produce genes encoding antigen proteins. Specifically, a vector capable of expressing the antigen gene is prepared and transferred into host cells to express the gene. The expressed antigen can then be purified. Antibodies can also be obtained by immunizing animals with the aforementioned genetically engineered antigen-expressing cells or cell lines expressing the antigen.

[0104] There are no particular limitations on the anti-TROP2 antibodies that can be used in this application; for example, antibodies specified by the amino acid sequence shown in the sequence listing of this application may preferably be used.

[0105] In some embodiments, the antibodies used in this application specifically bind to TROP2. In one particular embodiment, the anti-TROP2 antibody binds to the same epitope on TROP2 as sacrituzumab or datopotamab. In a more specific embodiment, the anti-TROP2 antibody has the same variable region CDR as sacrituzumab or datopotamab. In another more specific embodiment, the anti-TROP2 antibody has the same variable region (i.e., VH and VL) as sacrituzumab or datopotamab. In other embodiments, the antibodies used in this application include antibodies disclosed in previously published literature, including but not limited to, for example, CN115429893A.

[0106] In a preferred embodiment of this application, the anti-TROP2 antibody in the antibody-drug conjugate is selected from sacrituzumab or datopotamab.

[0107] In a preferred embodiment of this application, the anti-TROP2 antibody in the antibody-drug conjugate comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO: 1; HC-CDR2, which contains the amino acid sequence SEQ ID NO: 2; and HC-CDR3, which contains the amino acid sequence SEQ ID NO: 3; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO: 4; LC-CDR2, which contains the amino acid sequence SEQ ID NO: 5; and LC-CDR3, which contains the amino acid sequence SEQ ID NO: 6.

[0108] In a preferred embodiment of this application, the anti-TROP2 antibody in the antibody-drug conjugate comprises: VH, wherein V H The amino acid sequence SEQ ID NO: 7 or a variant thereof, the variant having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO: 7; and a VL containing the amino acid sequence SEQ ID NO: 8 or a variant thereof, the variant having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO: 8.

[0109] In a more preferred embodiment of this application, the anti-TROP2 antibody in the antibody-drug conjugate comprises: a heavy chain comprising the amino acid sequence SEQ ID NO: 9; and a light chain comprising the amino acid sequence SEQ ID NO: 10.

[0110] In a preferred embodiment of this application, the anti-TROP2 antibody in the antibody-drug conjugate comprises: V H The V H Contains the amino acid sequence SEQ ID NO: 11 or a variant thereof, said variant having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO: 11; and V L The V L It contains the amino acid sequence SEQ ID NO: 12 or a variant thereof, said variant having at least about 80% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence SEQ ID NO: 12.

[0111] In a more preferred embodiment of this application, the anti-TROP2 antibody in the antibody-drug conjugate comprises: a heavy chain comprising the amino acid sequence SEQ ID NO: 13; and a light chain comprising the amino acid sequence SEQ ID NO: 14.

[0112] Antibodies targeting other targets

[0113] Although not exemplified or emphasized in the embodiments of this application, other ADCs that include the linker-toxin disclosed in this disclosure and are conjugated with antibodies against other targets (such as anti-FRα (folate receptor α) antibodies, etc.) are still worth developing and studying.

[0114] Full-length antibody

[0115] In some embodiments, the antibody is a full-length antibody. In some embodiments, the full-length antibody is IgA, IgD, IgE, IgG, or IgM. In some embodiments, the full-length antibody includes a constant region of IgG, such as a constant region of IgG1, IgG2, IgG3, IgG4, or a variant thereof. In some embodiments, the full-length antibody includes a λ light chain constant region. In some embodiments, the long antibody includes a κ light chain constant region. In some embodiments, the full-length antibody is a human full-length antibody. In some embodiments, the full-length antibody includes a mouse immunoglobulin Fc sequence. In some embodiments, the full-length antibody includes an altered or otherwise modified Fc sequence such that it has enhanced effector functions of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

[0116] In some embodiments, any antibody described herein comprises an antibody heavy chain constant region and an antibody light chain constant region. In some embodiments, the antibody comprises an IgG1 heavy chain constant region. In some embodiments, the antibody comprises an IgG2 heavy chain constant region. In some embodiments, the antibody comprises an IgG3 heavy chain constant region. In some embodiments, the antibody comprises an IgG4 heavy chain constant region.

[0117] Binding affinity

[0118] Binding affinity is expressed as Kd, Koff, Kon, or Ka. As used herein, the term Koff refers to the rate constant for antibody dissociation from the antigen / antibody complex, determined by a kinetic selection device. The term Kon refers to the binding rate constant for antibody to bind to the antigen to form an antigen / antibody complex. The equilibrium dissociation constant Kd used herein refers to the dissociation constant for a specific antibody-antigen interaction, which is the antigen concentration required in the antibody molecule solution to occupy half of all antibody binding sites and reach equilibrium, equal to Koff / Kon. The determination of Kd assumes all binding molecules are in solution. For antibody-cell wall attachment, such as in yeast expression systems, the corresponding equilibrium dissociation rate constant is expressed as EC. 50 It is expressed as a good approximation of Kd. The affinity binding constant Ka is the reciprocal of the dissociation constant Kd.

[0119] The dissociation constant (Kd) can serve as an indicator of the affinity between an antibody moiety and an antigen. For example, a simple analysis can be performed using the Scatchard method with antibodies labeled with various markers and a Biacore instrument (manufactured by Amersham Biosciences), analyzing the interaction between biomolecules via surface plasmon resonance according to the user manual or accompanying kit. The Kd values ​​obtained using these methods are expressed in units of megohms (M). Antibodies that bind specifically to a target may have a Kd value, for example, ≤ 10. -7 M, ≤ 10 -8 M, ≤ 10 -9 M, ≤ 10 -10 M, ≤ 10 -11 M, ≤ 10 -12 M or ≤ 10 -13 The Kd value of M.

[0120] The binding specificity of antibodies can be experimentally determined using methods known in the art. These methods include, but are not limited to, Western blots, ELISA, RIA, ECL, IRMA, EIA, BIAcore assays, and peptide scanning.

[0121] In some embodiments, the Kd value of the antibody binding to the target is 10. -7 M to 10 -13 M (e.g., 10) -7 M to 10 -13 M, 10 -8 M to 10 -13 M, 10 -9 M to 10 -13 M or 10 -10 M to 10 -12 M). Therefore, in some embodiments, the Kd value for the binding between the antibody and the target is 10. -7 M to 10 -13 M, 1×10 -7 M to 5×10 -13 M, 10 -7 M to 10 -12 M, 10 -7 M to 10 -11 M, 10 -7 M to 10 -10 M, 10 -7 M to 10 -9 M, 10 -8 M to 10 -13 M, 1×10 -8 M to 5×10 -13 M, 10-8 M to 10 -12 M, 10 -8 M to 10 -11 M, 10 -8 M to 10 -10 M, 10 -8 M to 10 -9 M, 5×10 -9 M to 1×10 -13 M, 5×10 -9 M to 1×10 -12 M, 5×10 -9 M to 1×10 -11 M, 5×10 -9 M to 1×10 -10 M, 10 -9 M to 10 -13 M, 10 -9 M to 10 -12 M, 10 -9 M to 10 -11 M, 10 -9 M to 10 -10 M, 5×10 -10 M to 1×10 -13 M, 5×10 -10 M to 1×10 -12 M, 5×10 -10 M to 1×10 -11 M, 10 -10 M to 10 -13 M, 1×10 -10 M to 5×10 -13 M, 1×10 -10 M to 1×10 -12 M, 1×10 -10 M to 5×10 -12 M, 1×10 -10 M to 1×10 -11 M, 10 -11 M to 10 -13 M, 1×10 -11 M to 5×10 -13 M, 10 -11 M to 10 -12 M, 10 -12 M to 10 -13 M. In some embodiments, the Kd value of the binding between the antibody and the target is 10. -7 M to 10 -13 M.

[0122] Nucleic acid

[0123] Nucleic acid molecules encoding the antibodies described above are also considered. In some embodiments, a nucleic acid (or set of nucleic acids) encoding the full-length antibody described above is provided, including any of the full-length antibodies described herein. In some embodiments, the nucleic acid (or set of nucleic acids) of the antibody described herein may also include a nucleic acid sequence encoding a polypeptide tag (e.g., a protein purification tag, a His tag, a HA tag).

[0124] This paper also considers isolated host cells containing the aforementioned antibodies, isolated nucleic acids encoding the antibody polypeptide components, or vectors containing nucleic acids encoding the antibody polypeptide components described herein.

[0125] This application also includes variants of these nucleic acid sequences. For example, variants include nucleotide sequences that hybridize with nucleic acid sequences encoding antibodies of this application at least under moderately stringent hybridization conditions.

[0126] This application also provides a vector into which the nucleic acid sequence of this application can be inserted.

[0127] In short, by inserting a natural or synthetic nucleic acid encoding the antibody described herein into a suitable expression vector, such that the nucleic acid is operatively linked to 5' and 3' regulatory elements, including promoters (e.g., lymphocyte-specific promoters) and a 3' untranslated region (UTR), the antibody described herein (e.g., a full-length antibody) can be expressed. The vector is suitable for replication and integration in eukaryotic host cells. A typical cloning and expression vector contains transcription and translation terminators, a start sequence, and a promoter that regulate the expression of the target nucleic acid sequence.

[0128] The nucleic acids described in this application can also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols. Nucleic acid delivery methods are known in the art. See, for example, US Pat. Nos. 5,399,346, 5,580,859, 5,589,466, the entire contents of which are incorporated herein by reference. In some embodiments, this application also provides gene therapy vectors.

[0129] Nucleic acids can be cloned into many types of vectors. For example, nucleic acids can be cloned into vectors, including, but not limited to, plasmids, phage particles, phage derivatives, animal viruses, and Cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.

[0130] In addition, expression vectors can be provided to cells in the form of viral vectors. Viral vector technology is well known in the art and described, for example, in Green and Sambrook (2013, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and other virology or molecular biology manuals. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses. Typically, a suitable vector includes an origin of replication that functions in at least one organism, a promoter sequence, a convenient restriction endonuclease site, and one or more selection markers (see, for example, WO 01 / 96584; WO 01 / 29058; and US Pat. No. 6,326,193).

[0131] Numerous virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. Selected genes can be inserted into vectors and packaged into retroviral particles using techniques known in the art. The recombinant virus is then isolated and delivered in vivo or in vitro to the cells of a recipient. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In some embodiments, lentiviral vectors are used. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer because they enable long-term stable integration of transgenes and their propagation in daughter cells. Lentiviral vectors have additional advantages over tumor-derived retroviruses, such as murine leukemia virus, because they can transduce non-dividing cells, such as hepatocytes. They also have the additional advantage of low immunogenicity.

[0132] Other promoter elements, such as enhancers, regulate transcription initiation frequency. They are typically located 30-110 bp upstream of the start site, although recent studies have found that many promoters also contain functional elements downstream of the start site. The spacing between promoter elements is usually flexible, so the promoter retains its function even when elements interchange or move. In the thymidine kinase (TK) promoter, activity begins to decline only when the spacing between promoter elements increases to 50 bp.

[0133] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a very strong constitutive promoter sequence that can drive high-level expression of any polynucleotide sequence operatively linked to it. Another example of a suitable promoter is the elongation factor 1α (EF-1α) promoter. However, other constitutive promoters may also be used, including but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus long terminal repeat (HIV-LTR) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate early promoter, Rouss sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoters, myosin promoters, hemoglobin promoters, and creatine kinase promoters. Furthermore, this application should not be limited to the use of only constitutive promoters; inducible promoters are also considered in this application. The use of inducible promoters provides a molecular switch that initiates the expression of the polynucleotide sequence to which it is operable when such expression is needed, and shuts it off when not needed. Inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.

[0134] In some embodiments, the expression of the antibodies described herein is inducible. In some embodiments, the nucleic acid sequence encoding the antibody described herein is operatively linked to an inducible promoter, including any of the inducible promoters described herein.

[0135] Inducible promoter

[0136] The use of inducible promoters provides a molecular switch that initiates the expression of a polynucleotide sequence operatively linked to it when expression is desired, and shuts it off when expression is not desired. Exemplary inducible promoters suitable for eukaryotic cells include, but are not limited to, hormonal regulatory elements (e.g., see Mader, S. and White, JH (1993)). Proc. Natl. Acad. Sci. USA 90:5603-5607), synthetic ligand modulatory elements (see Spencer, DM) et al. (1993) Science 262: 1019-1024) and ionizing radiation modulation elements (see Manome, Y). et al. (1993) Biochemistry 32: 10607-10613; Datta, R. et al. (1992) Proc. Natl. Acad. Sci. USA 89: 1014-10153). For other exemplary inducible promoters applicable to in vivo or in vitro mammalian systems, see Gingrich. et al. (1998) Annual Rev. Neurosci21:377-405. In some embodiments, the inducible promoter system for expressing the antibody described herein is a Tet system. In some embodiments, the inducible promoter system for expressing the antibody described herein is an E. coli lac inhibitory system.

[0137] An exemplary inducible promoter system used in this application is the Tet system. This system is based on the Tet system described by Gossen et al. (1993). In an exemplary embodiment, the target polynucleotide is controlled by a promoter containing one or more Tet operon (TetO) sites. In the inactive state, the Tet repressor (TetR) binds to the TetO site and inhibits transcription of the promoter. In the active state, for example, in the presence of an inducer such as tetracycline (Tc), anhydrous tetracycline, doxycycline (Dox), or an active analog thereof, the inducer causes the TetR to be released from the TetO, thereby leading to transcription. Doxycycline is a member of the tetracycline antibiotic family, and its chemical name is 1-dimethylamino-2,4a,5,7-pentahydroxy-11-methyl-4,6-dioxy-1,4a,11,11a,12,12a-hexahydrotetraene-3-carboxamide.

[0138] In one embodiment, TetR is codon-optimized for expression in mammalian cells, such as mouse or human cells. Due to the degeneracy of the genetic code, most amino acids are encoded by more than one codon, resulting in a large number of variants of a given nucleic acid sequence without any change in the amino acid sequence it encodes. However, many organisms exhibit differences in codon usage, also known as "codon preference" (i.e., a preference for using specific codons for a given amino acid). Codon preference is often associated with the presence of a dominant tRNA species for a particular codon, which in turn improves the efficiency of mRNA translation. Therefore, codon optimization can be used to tailor coding sequences derived from a specific species (e.g., prokaryotes) to improve their expression in different species (e.g., eukaryotes).

[0139] Other specific variants of the Tet system include the following "Tet-Off" and "Tet-On" systems. In the Tet-Off system, transcription is inactivated in the presence of Tc or Dox. In this system, a tetracycline-regulated transcriptional activator protein (tTA), composed of TetR fused to the strong transcriptional activation domain of herpes simplex virus VP16, regulates the expression of target nucleic acids under the transcriptional control of tetracycline-responsive promoter elements (TREs). TRE elements consist of a TetO sequence tandemly fused to a promoter (typically a minimal promoter sequence derived from the immediate early promoter of human cytomegalovirus). In the absence of Tc or Dox, tTA binds to the TRE and activates transcription of the target gene. In the presence of Tc or Dox, tTA cannot bind to the TRE, and the target gene cannot be expressed.

[0140] Conversely, in the Tet-On system, transcription is activated in the presence of Tc or Dox. The Tet-On system is based on the inverse tetracycline-regulated transcriptional activator rtTA. Like tTA, rtTA is a fusion protein composed of a TetR repressor and a VP16 transcriptional activation domain. However, a four-amino acid change in the DNA-binding region of TetR alters the binding properties of rtTA, causing it to recognize only the tetO sequence on the target transgene TRE in the presence of Dox. Therefore, in the Tet-On system, rtTA can only activate the transcription of the TRE-regulated target gene in the presence of Dox.

[0141] The Lac repressor system functions by regulating the transcription of target polynucleotides operably linked to promoters containing the lac operon (lacO). The Lac repressor (lacR) binds to LacO, thereby preventing the transcription of the target polynucleotide. Expression of the target polynucleotide is induced by suitable inducers, such as isopropyl-β-D-thiogalactopyranoside (IPTG).

[0142] To assess the expression of a peptide or its fraction, the expression vector to be introduced into cells may also contain a selectable marker gene or a reporter gene, or both, to facilitate the identification and selection of expressing cells from a population of cells transfected or infected by a viral vector. In other respects, the selectable marker may be carried on a separate DNA fragment and used in co-transfection experiments. Both the selectable marker gene and the reporter gene may be side-mounted to a suitable regulatory sequence to enable its expression in the host cell. Useful selectable markers include, for example, antibiotic resistance genes such as neo and similar genes.

[0143] Reporter genes can be used to identify potential transfected cells and evaluate the function of regulatory sequences. Typically, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue; it encodes a polypeptide, and its expression exhibits easily detectable properties, such as enzymatic activity. Reporter gene expression is detected at an appropriate time after DNA is introduced into recipient cells. Suitable reporter genes may include those encoding luciferase, β-galactosidase, chloramphenicol acetyltransferase, secreted alkaline phosphatase, or green fluorescent protein (see Ui-Tel). et al., 2000 FEBS Letters 479: 79-82). Suitable expression systems are well-known and can be prepared using known techniques or obtained commercially. Typically, the smallest 5' flanking region that displays the highest expression level of the reporter gene is identified as the promoter. Such promoter regions can be linked to reporter genes and used to assess the ability of certain substances to regulate promoter-driven transcription.

[0144] In some embodiments, a nucleic acid encoding any of the full-length antibodies described herein is provided. In some embodiments, the nucleic acid comprises one or more nucleic acid sequences encoding the heavy and light chains of the full-length antibodies described herein. In some embodiments, each of the one or more nucleic acid sequences is contained in a separate vector. In some embodiments, at least some nucleic acid sequences are contained in the same vector. In some embodiments, all nucleic acid sequences are contained in the same vector. The vector may be selected from, for example, mammalian expression vectors and viral vectors (such as vectors derived from retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses).

[0145] Methods for introducing and expressing genes into cells are known in the art. In the context of expression vectors, vectors can be readily introduced into host cells, such as mammalian cells, bacterial, yeast, or insect cells, by any method in the art. For example, expression vectors can be introduced into host cells by physical, chemical, or biological methods.

[0146] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, liposome transfection, gene gun methods, microinjection, electroporation, and the like. Methods for preparing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Green and Sambrook (2013, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). In some embodiments, polynucleotides are introduced into host cells via calcium phosphate transfection.

[0147] Biological methods for introducing target polynucleotides into host cells include the use of DNA and RNA vectors. Viral vectors, particularly retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells. Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus type 1, adenoviruses, and adeno-associated viruses. See, for example, US Pat. Nos. 5,350,674 and 5,585,362.

[0148] Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as polymeric complexes, nanocapsules, microspheres, magnetic beads, and lipid-based systems, including oil-in-water emulsions, micelles, hybrid micelles, and liposomes. An exemplary colloidal system used as a delivery carrier in vivo and in vitro is a liposome (e.g., an artificial membrane capsule).

[0149] In the use of non-viral delivery systems, an exemplary delivery vector is the liposome. Consider using lipid formulations to introduce nucleic acids into host cells (in vitro, ex vivo, or in vivo). Alternatively, the nucleic acid can bind to lipids. Lipid-bound nucleic acids can be encapsulated within the aqueous interior of a liposome, dispersed within a lipid bilayer of the liposome, linked to the liposome by linkers that bind to both the liposome and oligonucleotides, embedded within the liposome, forming a complex with the liposome, dispersed in a solution containing lipids, mixed with lipids, bound to lipids, suspended in lipids, contained in or mixed with micelles, or otherwise bound to lipids. Lipids, lipid / DNA, or lipid / expression vector-related compositions in solution are not limited to any particular structure. For example, they may exist as a bilayer structure, as micelles, or as a “collapsed” structure. They may also be simply dispersed in solution, possibly forming aggregates of varying sizes or shapes. Lipids are fatty substances and can be naturally occurring or synthetic. For example, lipids include fat droplets that are naturally present in the cytoplasm, as well as a class of compounds containing long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.

[0150] Regardless of the method used to introduce exogenous nucleic acids into host cells or otherwise expose cells to the inhibitors of this application, a variety of experiments can be performed to confirm the presence of the recombinant DNA sequence in the host cells. These experiments include, for example, "molecular biology" experiments well known to those skilled in the art, such as Southern and Northern blotting, RT-PCR, and PCR; and "biochemical" experiments, such as detecting the presence or absence of a specific polypeptide, for example, identification by immunological methods (ELISAs and Western blots) or by the experiments described herein, all of which fall within the scope of this application.

[0151] Preparation of antibodies

[0152] In some embodiments, the antibody described herein is a monoclonal antibody or is derived from a monoclonal antibody. In some embodiments, the antibody comprises V derived from a monoclonal antibody. H and V L Or its variants. In some embodiments, the antibody further comprises C from a monoclonal antibody. H 1 and C L Regions, or their variants. Monoclonal antibodies can be prepared using methods known in the art, including hybridoma cell methods, phage display methods, or methods using recombinant DNA.

[0153] In hybridoma cell methods, hamsters, mice, or other suitable host animals are typically immunized with an immunomodulator to induce the production or ability to produce antibodies that specifically bind to the immunomodulator. Alternatively, lymphocytes can be immunized in vitro. The immunomodulator may include a peptide or fusion protein of the target protein. Peripheral blood lymphocytes (PBLs) are typically used if human cells are desired, while spleen cells or lymph node cells are used if non-human mammalian cells are desired. The lymphocytes are fused with an immortalized cell line using a suitable fusion agent, such as polyethylene glycol, to form hybridoma cells. Immortalized cell lines are typically transformed mammalian cells, particularly rodent, bovine, and human myeloma cells. Rat or mouse myeloma cell lines are commonly used. Hybridoma cells can be cultured in a suitable culture medium, preferably containing one or more substances that inhibit the growth or survival of unfused immortalized cells. For example, if the parental cells lack hypoxanthine-guanine phosphoribosyltransferase (HGPRT or HPRT), the hybridoma cell culture medium typically includes hypoxanthine, aminopterin, and thymidine (HAT medium), which inhibits the growth of HGPRT-deficient cells.

[0154] In some embodiments, the immortalized cell lines are efficiently fused, ensuring high-level and stable antibody expression through selected antibody-producing cells, and are sensitive to certain culture media, such as HAT medium. In some embodiments, the immortalized cell lines are mouse myeloma cell lines, obtainable from, for example, the Salk Cell Collection in San Diego, California, and the American Collection of Type Cultures in Manassas, Virginia. Human myeloma and mouse-human hybrid myeloma cell lines for the preparation of human monoclonal antibodies are also described.

[0155] The presence of monoclonal antibodies against the peptide can then be determined in the culture medium of hybridoma cells. The binding specificity of monoclonal antibodies produced by hybridoma cells can be determined by immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). Such techniques or analytical methods are known in the art. The binding affinity of monoclonal antibodies can be determined, for example, by Munson and Pollard... Anal. Biochem The Scatchard analysis described in ., 107:220 (1980) confirms this.

[0156] After identifying the desired hybridoma cells, the target clone can be subcloned using limiting dilution and cultured using standard methods. Suitable media for this purpose include, for example, modified Eagle medium (DMEM) and RPMI-1640 medium. Alternatively, hybridoma cells can be grown in mammals as ascites fluid.

[0157] Subclonal secreted monoclonal antibodies can be isolated or purified from culture medium or ascites using conventional immunoglobulin purification methods, such as protein A-agarose gel, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0158] In some embodiments, according to any of the antibodies described herein, the antibody comprises a sequence selected from an antibody library (e.g., a phage library displaying scFv or Fab fragments). The clone can be identified by screening antibody fragment combination libraries with the desired activity. For example, various methods are known in the art for generating phage display libraries and screening these libraries to obtain antibodies with the desired binding properties. These methods are used in, for example, Hoogenboom... et al., Methods in Molecular Biology 178:1-37 (O'Brien) et al., ed., Human Press, Totowa, N.J A review was conducted in (., 2001), and in, for example, McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol .222: 581-597 (1992); Marks and Bradbury, Methods in Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, N.J. (2003); Sidhu et al., J. Mol. Biol .338(2): 299-310 (2004); Lee et al., J. Mol. Biol . 340(5): 1073-1093 (2004);Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al., J. Immunol. Methods Further description is given in 284(1-2): 119-132 (2004).

[0159] In some phage display methods, V is cloned separately using polymerase chain reaction (PCR). H and V L All components of the gene are randomly recombined in a phage library, and then phages capable of binding antigens, such as Winter, are screened. et al., Ann. Rev. ImmunolAs described in ., 12: 433-455 (1994). Phages typically present antibody fragments as scFv fragments or Fab fragments. Immunogenically derived phage libraries provide high-affinity antibodies against immunogens without the need to construct hybridoma cells. Alternatively, natural libraries (e.g., from humans) can be cloned to provide a single source of antibodies against a variety of non-self and self antigens without any immunization, as Griffiths did. et al., EMBO J As described in , 12: 725-734 (1993). Finally, natural libraries can also be prepared by cloning a non-rearranged V-gene fragment from stem cells, encoding the CDR3 hypervariable region using PCR primers containing random sequences, and performing rearrangement in vitro, as described in Hoogenboom and Winter, J. Mol. Biol As described in ., 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example, US Pat. No. 5,750,373 and US Patent Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936 and 2009 / 0002360.

[0160] Antibodies can be screened and prepared using phage display technology. This library can be a human scFv phage display library with at least 1×10⁻⁶ cells / mL. 9 (e.g., at least 1 × 10) 9 2.5 × 10 9 5 × 10 9 7.5 × 10 9 1 × 10 10 2.5 × 10 10 5 × 10 10 7.5 × 10 10 Or 1 × 10 11This library contains a diverse range of unique human antibody fragments. In some embodiments, the library is a natural human library constructed from DNA extracted from PMBCs and spleen of healthy subjects, containing all heavy and light chain subfamilies. In some embodiments, the library is a natural human library constructed from DNA extracted from PMBCs isolated from patients with various diseases, such as patients with autoimmune diseases, cancer patients, and patients with infectious diseases. In some embodiments, the library is a semi-synthetic human library in which the heavy chain CDR3 is completely randomized, and all amino acids (except cysteine) are present at any given position with equal probability. (See, for example, Hoet, RM) et al., Nat. Biotechnol . 23(3):344-348, 2005). In some embodiments, the heavy chain CDR3 length of the semi-synthetic human library is between 5 and 24 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24). In some embodiments, the library is a fully synthetic phage display library. In some embodiments, the library is a non-human phage display library.

[0161] Phage clones with high affinity for a target can be screened by iterative binding of the phage to the target, which is bound to a solid support (e.g., beads for solution panning or mammalian cells for cell panning), followed by removal of unbound phages and elution of specifically bound phages. The eluted phage clones are then used to infect suitable host cells, such as E. coli XL1-Blue, for expression and purification. Multiple rounds of panning (e.g., 2, 3, 4, 5, 6, or more rounds), such as solution panning, cell panning, or a combination of both, can be used to enrich phage clones bound to the target. The binding of the enriched phage clones to the target can be detected by any method known in the art, including, for example, ELISA and FACS.

[0162] Another method for screening antibody libraries is to display proteins on the surface of yeast cells. Wittrup et al. (US Patents 6,699,658 and 6,696,251) developed a method for displaying yeast cells. In this yeast display system, one component includes a yeast lectin protein (Aga1) anchored to the yeast cell wall, and another component includes a second subunit of the lectin protein Aga2, which can bind to the Aga1 protein via disulfide bonds and thus be displayed on the yeast cell surface. The Aga1 protein is expressed by integrating the Aga1 gene into the yeast chromosome. A single-stranded variable fragment (scFv) library is fused with the Aga2 gene in a yeast display plasmid, and after transformation, the library is retained in the yeast due to the presence of additional nutrient markers. Both Aga1 and Aga2 proteins are expressed under the control of a galactose-inducible promoter.

[0163] Human Antibody V Gene Library (V H and V K The fragment was obtained using a set of degenerate primers via PCR (Sblattero, D. and Bradbury, A. Immunotechnology 3, 271-278 (1998). PCR templates were derived from commercially available RNA or cDNA, including PBMCs, spleen, lymph nodes, bone marrow, and tonsils. Independent V... H and V K After PCR library merging, they were assembled into scFv form (Sheets, MD) using overlap extension PCR. et al, Proc. Natl. Acad. Sci. USA 95, 6157–6162 (1998). To construct a yeast scFv display library, the obtained scFv PCR product was cloned into a yeast display plasmid via homologous recombination. (Chao, G, 1998) et al, Nat Protoc . 2006;1(2):755-68.Miller KD, et al. Current Protocols in Cytometry 4.7.1-4.7.30, 2008).

[0164] The antibodies described herein can be screened using mammalian cell display systems, where the antibody portion is displayed on the cell surface and antigen-directed screening methods are used to isolate antibodies that specifically bind to the target (as described in US patent No. 7,732,195B2). Chinese hamster ovary (CHO) cell libraries displaying large amounts of human IgG antibody genes can be constructed and used to discover clones expressing high-affinity antibody genes. Another display system has been developed that uses alternative splicing to simultaneously display and secrete the same protein on the cell surface, where the displayed protein phenotype remains genotype-dependent, allowing for simultaneous characterization of the secreted soluble antibody in both biophysical and cell function-based analyses. This method overcomes many limitations of previous mammalian cell display methods, enabling direct screening and maturation of antibodies in full-length, glycosylated IgG forms (Peter M. Bowers, et al, Methods (2014, 65: 44-56). Transient expression systems are suitable for single-round antigen selection before antibody gene recovery, and are therefore most useful for selecting antibodies from smaller libraries. Stable exon vectors offer an attractive option. Exon vectors can be efficiently transfected and stably maintained at low copy numbers, allowing for multiple rounds of panning and the analysis of more complex antibody libraries.

[0165] The IgG library was constructed by linking germline sequences of the V gene fragment isolated from a group of human donors with rearranged (D)J regions. RNA collected from 2000 human blood samples was reverse transcribed into cDNA, and V was used... H and V K Specific primer amplification V H and V K The fragment was extracted and purified by gel extraction. V H and V K Fragments were subcloned into display vectors containing either the IgG1 or K constant region, and then electroporated or transduced into 293T cells to prepare IgG libraries. To prepare scFv antibody display libraries, V... H and V K The scFv is generated, then subcloned into a display vector, and then electroporated or transduced into 293T cells. It is well known that IgG libraries are constructed based on germline sequence V gene fragments isolated from a group of donors and rearranged (D)J regions; donors can be mice, rats, rabbits, or monkeys.

[0166] Monoclonal antibodies can also be prepared using recombinant DNA methods, such as those described in US Patent No. 4,816,567. The DNA encoding the monoclonal antibody described in this application can be easily isolated and sequenced using conventional methods, such as using oligonucleotide probes that specifically bind to genes encoding the light and heavy chains of murine antibodies. Hybridoma cells as described above or phage clones of this application that bind to specific targets can serve as sources of this DNA. After isolation, the DNA can be placed in an expression vector, which is then transfected into host cells, such as simian COS cells, Chinese hamster ovary cancer (CHO) cells, or non-immunoglobulin-producing myeloma cells, to obtain monoclonal antibodies synthesized in recombinant host cells. The DNA can also be modified, for example, by replacing the human heavy and light chain constant regions with coding sequences and / or replacing homologous non-human sequences with frame regions (US Patent No. 4,816,567; Morrison). et al., supra Alternatively, the coding sequence of an immunoglobulin may be covalently linked to all or part of the coding sequence of a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide may replace the constant region of the antibody in this application, or may replace an antigen-binding site in the variable domain of the antibody in this application, forming a chimeric bivalent antibody.

[0167] The antibody may be a monovalent antibody. Methods for preparing monovalent antibodies are known in the art. For example, a recombinant expression method involving immunoglobulin light chains and modified heavy chains. Typically, the heavy chain is truncated at any position in the Fc region to prevent cross-linking between the heavy chains. Alternatively, relevant cysteine ​​residues are substituted with other amino acid residues or deleted to prevent cross-linking.

[0168] In vitro methods are also suitable for preparing monovalent antibodies. Digesting antibodies to produce antibody fragments, particularly Fab fragments, can be accomplished using any method known in the art.

[0169] Antibody variable domains with the desired binding specificity (antibody-antigen binding site) can be fused to immunoglobulin constant regions. Fusion is preferably with immunoglobulin heavy chain constant regions, which include at least a partial hinge, CH2, and CH3 regions. In some embodiments, a first heavy chain constant region (CH1) containing the necessary light chain binding site is present in at least one fusion. DNA encoding the immunoglobulin heavy chain fusion, and optionally DNA encoding the immunoglobulin light chain, is inserted into a separate expression vector and co-transfected into a suitable host organism.

[0170] Fully human and humanized antibodies

[0171] The antibodies described herein (such as full-length antibodies) can be fully human antibodies or humanized antibodies. Humanized forms of non-human (e.g., mouse) antibody portions are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, scFv, or other antigen-binding sequences of the antibody), typically comprising a minimal sequence derived from a non-human immunoglobulin. Humanized antibodies comprise human immunoglobulins, immunoglobulin chains, or fragments thereof (receptor antibodies), wherein residues of the receptor CDR are replaced by non-human (donor antibody) CDR residues having the desired specificity, affinity, and performance, such as mouse, rat, or rabbit CDRs. In some embodiments, human immunoglobulin Fv frame region residues are replaced by corresponding non-human residues. Humanized antibodies may also contain amino acid residues that are neither part of the receptor antibody nor present in the introduced CDR or frame region sequence. Typically, humanized antibodies contain at least one, usually two, variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of the non-human immunoglobulin, and all or substantially all of the frame regions are human immunoglobulin common sequences.

[0172] Typically, humanized antibodies contain one or more amino acid residues introduced from non-human sources. These non-human amino acid residues are often referred to as "shift-in" residues and usually originate from "shift-in" variable domains. According to some embodiments, humanization can be performed essentially as described by Winter and colleagues (Jones...). et al., Nature , 321: 522-525 (1986); Riechmann et al., Nature , 332: 323-327 (1988); Verhoeyen et al., Science , 239: 1534-1536 (1988)), by replacing the corresponding sequences of human antibodies with rodent CDRs or CDR sequences. Thus, this "humanized" antibody motif (US Patent No. 4,816,567), which is essentially less than a complete human antibody, has its variable domains replaced by corresponding sequences from non-human sources. In practice, humanized antibody motifs are typical human antibody motifs in which some CDR residues and possibly some framework region residues are replaced by residues from similar sites in rodent antibodies.

[0173] Fully human antibodies are an alternative to humanization. For example, it is now possible to produce transgenic animals (e.g., mice) that generate a complete fully human antibody library after immunization without producing endogenous immunoglobulins. For instance, it has been reported that homozygous deletion of the antibody heavy chain linker (JH) gene in chimeric and germline mutant mice completely suppresses the production of endogenous antibodies. Transferring human germline immunoglobulin gene arrays into such germline mutant mice can generate human antibodies upon antigen stimulation; see, for example, akobovits. et al., PNAS USA , 90:2551 (1993); Jakobovits et al., Nature , 362:255-258 (1993); Bruggemann et al., Year in Immunol ., 7:33 (1993); US Patent Nos. 5,545,806, 5,569,825, 5,591,669, 5,545,807; and WO 97 / 17852. Alternatively, fully human antibodies can be prepared by introducing human immunoglobulin gene loci into transgenic animals (e.g., mice in which endogenous immunoglobulin genes have been partially or completely silenced). Upon antigen stimulation, the production of fully human antibodies is found to be very similar to its production in humans in all aspects, including gene rearrangement, assembly, and antibody library. This method is illustrated in, for example, US Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016, and Marks et al., Bio / Technology , 10: 779-783 (1992); Lonberg et al., Nature , 368: 856-859 (1994); Morrison, Nature , 368: 812-813 (1994); Fishwild et al., Nature Biotechnology , 14: 845-851 (1996); Neuberger, Nature Biotechnology , 14: 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol It is described in ., 13: 65-93 (1995).

[0174] Fully human antibodies can also be produced by in vitro activation of B cells (see US Patents 5,567,610 and 5,229,275) or by using various techniques known in the art, including phage display libraries. Hoogenboom and Winter,J. Mol. Biol ., 227:381 (1991); Marks et al., J. Mol. Biol ., 222:581 (1991). Cole et al And Boerner et al The techniques employed by Cole et al. can also be used to prepare fully human monoclonal antibodies. See Cole. et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss , p.77 (1985) and Boerner et al., J. Immunol ., 147(1): 86-95(1991).

[0175] Antibody variants

[0176] In some embodiments, the amino acid sequences of the antibody variants (e.g., full-length antibodies) provided herein are also considered. For example, it may be necessary to improve the binding affinity and / or other biological activities of the antibody. The amino acid sequences of antibody variants can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues in the antibody amino acid sequence. The final construction can be accomplished by any combination of amino acid residue deletions, insertions, and substitutions to give it the desired characteristics, such as antigen binding.

[0177] In some embodiments, antibody variants with one or more amino acid substitutions are provided. Target sites for substitution mutations include hypervariable regions (HVRs) and frame regions (FRs). Amino acid substitutions can be introduced into the target antibody to screen for products with desired activities, such as improved biological activity, maintenance / improvement of antigen-binding ability, reduced immunogenicity, or improved ADCC or CDC.

[0178] Conservative substitutions are shown in Table A below.

[0179] Table A: Conservative Substitution

[0180]

[0181] Amino acids are classified into different categories based on the properties of their side chains:

[0182] a. Hydrophobic amino acids: Norleucine, Methionine (Met), Alanine (Ala), Valine (Val), Leucine (Leu), Isoleucine (Ile);

[0183] b. Neutral hydrophilic amino acids: Cysteine ​​(Cys), Serine (Ser), Threonine (Thr), Asparagine (Asn), Glutamine (Gln);

[0184] c. Acidic amino acids: Aspartic acid (Asp), Glutamic acid (Glu);

[0185] d. Basic amino acids: Histidine (His), Lysine (Lys), Arginine (Arg);

[0186] e. Contains amino acids that affect chain direction: glycine (Gly) and proline (Pro);

[0187] f. Aromatic amino acids: tryptophan (Trp), tyrosine (Tyr), phenylalanine (Phe).

[0188] Substitution of non-conservative amino acids involves replacing one class with another.

[0189] An exemplary substitution variant is an affinity-matured antibody, which can be conveniently generated using affinity maturation techniques, such as phage display-based techniques. In short, one or more CDR residues are mutated, the variant antibody is partially displayed on a phage, and variants with specific biological activities (e.g., increased affinity for the antigen) are screened. Alterations (e.g., substitutions) can be made in HVR regions to obtain improved affinity. Alterations can be made in “hotspot regions” of the HVR, i.e., residues encoded by codons that are frequently mutated during somatic maturation (see, for example, Chowdhury). Methods Mol. Biol . 207:179-196 (2008)), and / or at specific determinant residues (SDRs), the resulting variant V was detected H and V L Binding affinity. Methods for constructing and reselecting affinity maturities from secondary libraries have been described in some literature, such as Hoogenboom. et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ ,(2001)).

[0190] In some examples of affinity maturation, diversity is introduced into selected variable genes for affinity maturation using any of a variety of methods (e.g., error-prone PCR, strand shuffling, or oligonucleotide directed mutagenesis). A secondary library is then created. This library is screened to identify antibody variants with the desired affinity. Another method for introducing diversity includes an HVR-mediated approach, where several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding are specifically identified, for example, through alanine scan mutagenesis or modeling. Typically, the CDR-H3 and CDR-L3 regions are particularly key targets.

[0191] In some embodiments, substitution, insertion, or deletion may occur within one or more HVRs, provided that such change does not substantially reduce the antibody's ability to bind to the antigen. For example, conserved changes that do not substantially reduce binding affinity (e.g., conserved substitutions provided herein) may be produced in HVRs. These changes may occur outside the HVR "hotspot" or SDR regions. In some embodiments, variants V provided above... H and V L Each HVR sequence is either unchanged or contains no more than one, two, or three amino acid substitutions.

[0192] A useful method for identifying amino acid residues or regions in an antibody that can be targeted for mutation is called "alanine scanning mutation," as exemplified by Cunningham and Wells (1989). Science As described in 244:1081-1085, in this method, one or a group of target residues (e.g., charged residues such as arginine, aspartic acid, histidine, lysine, and glutamic acid) are substituted with neutral or negatively charged amino acids (e.g., alanine or glutamic acid) to determine whether antibody-antigen interaction is affected. Substitutions may be further introduced at the amino acid positions to demonstrate that the position is functionally sensitive to the initial substitution. Alternatively / additionally, contact sites between the antibody and antigen are identified by the crystal structure of the antigen-antibody complex. These contact site residues and adjacent residues can be targeted or eliminated as substitution candidates. Variants are screened to determine if they possess the desired properties.

[0193] Amino acid sequence insertions, including fusions at the amino and / or carboxyl ends, can range in length from one residue to polypeptides containing 100 or more residues, and also include the insertion of one or more amino acid residues within the sequence. Examples of terminal insertions include antibodies with a methionyl residue at the N-terminus. Other insertion variants of antibody molecules include polypeptides with an enzyme (e.g., ADEPT) fused to the N-terminus or C-terminus of the antibody molecule or those that increase the antibody's serum half-life.

[0194] Fc region variant

[0195] In some embodiments, one or more amino acid modifications are introduced into the Fc region of an antibody (e.g., a full-length antibody or antibody fusion protein) described herein, thereby producing an Fc region variant. In some embodiments, the Fc region variant has enhanced ADCC efficacy, typically associated with Fc-binding receptors (FcRs). In some embodiments, the Fc region variant has reduced ADCC efficacy. There are numerous examples of how alterations or mutations in the Fc sequence affect its efficacy, such as WO 00 / 42072 and Shields. et al. J Biol. Chem9(2):6591-6604 (2001) describes antibody variants that enhance or weaken binding to FcRs. The contents of these publications are incorporated herein by reference.

[0196] Antibody-dependent cell-mediated cytotoxicity (ADCC) is the mechanism of action of therapeutic antibodies against tumor cells. ADCC is a cell-mediated immune defense mechanism in which effector cells of the immune system actively lyse target cells (e.g., cancer cells) when antigens on the surface of target cells are bound by specific antibodies. Typically, ADCC effects involve antibody-activated NK cells. NK cells express the Fc receptor CD16. This receptor recognizes and binds to the Fc portion of antibody molecules bound to the surface of target cells. The most common Fc receptors on the surface of NK cells are CD16 or FcγRIII. Binding of the Fc receptor to the Fc region of the antibody leads to NK cell activation, release of cytolytic granules, and subsequent apoptosis of the target cells. The cytotoxic effect of ADCC on tumor cells can be determined through specificity assays using NK-92 cells transfected with high-affinity FcRs. The results were compared with those of wild-type NK-92 cells that do not express FcRs.

[0197] In some embodiments, this application also provides a variant of the antibody described herein (e.g., a full-length antibody variant) comprising an Fc region having some, but not all, of the effector functions, resulting in an extended half-life in vivo, where the specific effector function (e.g., CDC or ADCC) is non-essential or detrimental. Such an antibody is a desirable candidate for this application. The reduction / elimination of CDC and / or ADCC activity is confirmed by in vitro and / or in vivo cytotoxicity assays. For example, an Fc receptor (FcR) binding assay confirms that the antibody lacks FcγR binding capacity (and therefore may lack ADCC activity) but retains FcRn binding capacity. In the main cells mediating ADCC, NK cells express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. Ravetch and Kinet Annu. Rev. Immunol Table 3 on page 464 of 9:457-492 (1991) summarizes the expression of FcR on hematopoietic cells. Non-limiting examples of in vitro assessment of ADCC activity of target molecules are described in US Pat. No. 5,500,362 (see, for example, Hellstrom, I). et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); US Pat. No. 5,821,337 (see Bruggemann,M. et al., J. Exp. Med 166:1351-1361 (1987). Alternatively, non-radioactive detection methods can be used (see, for example, ACTI™ flow cytometry non-radioactive cytotoxicity assay (Cell Technology, Inc. MountainView, Calif.) and CYTOTOX 96™ non-radioactive cytotoxicity assay (Promega, Madison, Wis.)). Effector cells used in such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively, the ADCC activity of the target molecule can be detected in vivo, for example in animal models such as Clynes. et al. Proc. Nat' Acad. Sci. USA As described in 95:652-656 (1998). A C1q binding assay can also be performed to confirm that the antibody cannot bind to C1q, thus lacking CDC activity. See, for example, C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay can be performed (see, for example, Gazzano-Santoro et al.). al., J. Immunol. Methods 202:163 (1996); Cragg, MS et al., Blood 101:1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103:2738-2743 (2004)). The binding and in vivo clearance / half-life of FcRn were determined using methods known in the art (see, e.g., Petkova, SB). et al., Int'l. Immunol . 18(12):1759-1769(2006)).

[0198] Antibodies with reduced effector function include those with one or more residue substitutions at positions 238, 265, 269, 270, 297, 327, and 329 in the Fc region (US Pat. No. 6,737,056). These Fc variants include those with two or more residue substitutions at positions 265, 269, 270, 297, and 327, including the Fc variant known as “DANA,” which has alanine substitutions at positions 265 and 297 (US Pat. No. 7,332,581).

[0199] Antibody variants with increased or decreased binding affinity to FcRs have been described (see, for example, US Pat. No. 6,737,056; WO 2004 / 056312, and Shields). et al., J. Biol. Chem . 9(2):6591-6604(2001)).

[0200] In some embodiments, a variant of the antibody described herein (e.g., a full-length antibody) is provided comprising an Fc region variant having one or more amino acid substitutions capable of enhancing the ADCC effect. In some embodiments, the Fc region variant comprises one or more amino acid substitutions capable of enhancing the ADCC effect, these substitutions being located at positions 298, 333, and / or 334 (EU residue number) of the Fc region. In some embodiments, the antibody (e.g., a full-length antibody) variant includes amino acid substitutions at positions S298A, E333A, and K334A of the Fc region.

[0201] In some embodiments, alterations in the Fc region lead to changes (i.e., enhancement or attenuation) in C1q binding and / or complement-dependent cytotoxicity (CDC), see US Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al., J. Immunol As described in 164:4178-4184 (2000).

[0202] In some embodiments, a variant of the antibody described herein (e.g., a full-length antibody) is provided comprising an Fc region variant having one or more amino acid substitutions that can prolong half-life or enhance binding to an Fc receptor (FcRn). Antibodies with prolonged half-life and improved FcRn binding are described in US 2005 / 0014934A1 (Hinton et al.). These antibodies contain one or more amino acid substitutions in the Fc region that enhance the binding of the Fc region to FcRn. These Fc variants contain one or more substitutions of residues at positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, or 434 in the Fc region, for example, the substitution of residue 434 in the Fc region (US Pat. No. 7,371,826).

[0203] See also Duncan & Winter. NatureExamples of other Fc region variants are provided in US Pat. No. 5,648,260; US Pat. No. 5,624,821 and WO 94 / 29351.

[0204] This application considers antibodies (e.g., full-length antibodies) including any of the Fc variants or combinations thereof described herein.

[0205] Glycosylation variants

[0206] In some embodiments, the antibodies (e.g., full-length antibodies) provided herein are modified to increase or decrease the degree of antibody glycosylation. Adding or deleting glycosylation sites on antibodies can be conveniently achieved by altering the amino acid sequence of the antibody or its polypeptide moiety to add or remove one or more glycosylation sites.

[0207] The antibodies described herein contain an Fc region that can be altered to the sugars linked to it. Naturally occurring antibodies produced by mammalian cells typically contain branched, biantennary oligosaccharides, which are usually linked to the CH2 domain Asn297 of the Fc region via N-linkage, see, for example, Wright. et al., TIBTECH 15:26-32 (1997). The oligosaccharide may comprise various sugars, such as mannose, N-acetylglucosinolate (GlcNAc), galactose, and sialic acid, as well as trehalose linked to the GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, the antibody of this application may be modified with oligosaccharides to produce antibody variants with certain improved properties.

[0208] The N-glycan linked to the CH2 domain of the Fc region is heterogeneous. Antibodies or Fc fusion proteins produced in CHO cells are fucosylated via fucosyltransferase activity; see Shoji-Hosaka. et al., J. Biochem 2006, 140:777-83. Typically, a small subset of naturally occurring non-fucosylated IgGs can be detected in human serum. N-glycosylation of the Fc region is important for its binding to FcγR; while non-fucosylated N-glycans enhance the binding affinity of Fc to FcγRIIIa. Enhanced binding affinity to FcRIIIa leads to enhanced ADCC effects, which is advantageous in certain antibody therapeutic applications requiring cytotoxicity.

[0209] In some embodiments, enhanced effector function may be detrimental when Fc-mediated cytotoxicity is not required. In some embodiments, the Fc fragment or CH2 domain is non-glycosylated. In some embodiments, glycosylation is prevented by mutating the N-glycosylation site in the CH2 domain.

[0210] In some embodiments, variants of the antibodies described herein (e.g., full-length antibodies) are provided that include an Fc region, wherein the glycosylation structure linked to the Fc region has reduced or no fucose, which may enhance ADCC function. Specifically, the antibodies provided herein have reduced fucose relative to the same antibodies produced by wild-type CHO cells. That is, they are characterized by having less fucose than antibodies produced by native CHO cells (e.g., CHO cells producing the native glycosylated form, CHO cells containing the native FUT8 gene). In some embodiments, the N-linked glycan of the antibody has less than 50%, 40%, 30%, 20%, 10%, or 5% fucose. For example, the fucose content of the antibody may be 1%-80%, 1%-65%, 5%-65%, or 20%-40%. In some embodiments, the N-linked glycan of the antibody does not contain fucose, i.e., the antibody is completely fucose-free, or has no fucose or is defucosylated. The fucose content is determined by calculating the average fucose content within the sugar chain linked to Asn297 relative to the total amount of all sugar structures (such as complex, hybrid, or mannose structures) linked to Asn297 as measured by MALDI-TOF mass spectrometry, as described in WO 2008 / 077546. Asn297 refers to the asparagine residue located at position 297 of the Fc region (EU Fc region residue numbering system). However, due to minor sequence variations in antibodies, Asn297 can also be located ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. These fucoidylated variants may have enhanced ADCC function. See, for example, US Patent Publication Nos. US 2003 / 0157108 (Presta, L.), US 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Examples of publications associated with antibody variants that are “defucosylated” or “fucosylated” include: US 2003 / 0157108; WO2000 / 61739; WO 2001 / 29246; US 2003 / 0115614; US 2002 / 0164328; US 2004 / 0093621; US2004 / 0132140; US 2004 / 0110704; US 2004 / 0110282; US 2004 / 0109865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO 2005 / 035778; WO 2005 / 053742; WO 2002 / 031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng 87:614 (2004). Cell lines capable of producing defucosylation antibodies include Lec13 CHO cells (Ripka) lacking protein fucosylation function. et al. Arch. Biochem. Biophys . 249:533-545 (1986); US Pat Appl No US 2003 / 0157108 A1, Presta, L; and WO 2004 / 056312 A1, Adams et al (especially Example 11), and gene knockout cell lines, such as CHO cells with α-1,6-fucosyltransferase gene and FUT8 gene knockout (see Yamane-Ohnuki). et al. Biotech. Bioeng . 87:614 (2004); Kanda, Y. et al., Biotechnol. Bioeng ., 94(4):680-688 (2006); and WO2003 / 085107).

[0211] Variants of the antibodies described herein (e.g., full-length antibodies) further provide bimeric oligosaccharides, for example, wherein the biantennary oligosaccharide linked to the Fc region of the antibody is bimeric by GlcNAc. Such antibody (e.g., full-length antibody) variants may have reduced fucosylation and / or enhanced ADCC function. Examples of such antibody variants are described in WO 2003 / 011878 (Jean-Mairet). et al .); US Pat. No. 6,602,684 (Umana et al .); US 2005 / 0123546 (Umana et al .), and Ferrara et al., Biotechnology and Bioengineering As described in , 93(5):851-861 (2006). Variants of the antibodies described herein (e.g., full-length antibodies) are also provided, having at least one galactose residue in the oligosaccharide linked to the Fc region. These antibody variants may have enhanced CDC function. Such variants are described, for example, in WO 1997 / 30087 (Patel). et al It is described in WO 1998 / 58964 (Raju, S.) and WO 1999 / 22764 (Raju, S.).

[0212] In some embodiments, variants of the antibody (e.g., full-length antibody) include an Fc region capable of binding to FcγRIII. In some embodiments, the antibody (e.g., full-length antibody) variant containing the Fc region has ADCC activity in the presence of human effector cells (e.g., T cells), or has enhanced ADCC activity in the presence of human effector cells compared to other identical antibodies (e.g., full-length antibodies) having a human wild-type IgG1 Fc region.

[0213] Cysteine ​​engineered variants

[0214] In some embodiments, it is necessary to prepare cysteine-engineered antibodies (e.g., full-length antibodies) in which one or more amino acid residues are replaced by cysteine ​​residues. In some embodiments, the substituted residues are located at accessible sites on the antibody. By replacing those residues with cysteine, an active thiol group is located at an accessible site on the antibody, which can be used to conjugate the antibody to other parts, such as a pharmaceutical part or a linker-pharmaceutical part, to prepare immunoconjugates as further described herein. Cysteine-engineered antibodies (e.g., full-length antibodies) can be prepared according to, for example, US Pat. No. 7,521,541.

[0215] derivative

[0216] In some embodiments, the antibodies (e.g., full-length antibodies) provided herein may be further modified to include other non-protein moieties known in the art and readily available. Suitable moieties for derivatizing antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homogeneous or random copolymers), dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymers, propylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde is advantageous in manufacturing due to its stability in water. Polymers can have any molecular weight and can be branched or unbranched. The number of polymers attached to an antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. Typically, the number and / or type of polymers used for derivatization are determined based on considerations including, but not limited to, the need to improve the properties or function of the antibody, and whether the antibody derivative is intended for treatment under specific conditions.

[0217] Toxins (also known as antitumor compounds, cytotoxic drugs, or payloads)

[0218] Topoisomerase I inhibitor

[0219] The toxin of the antibody-drug conjugate in this application is a topoisomerase I inhibitor. A topoisomerase I inhibitor is a compound capable of forming a ternary complex with topoisomerase I and DNA, thereby preventing DNA rejoining and introducing DNA strand breaks into the cellular genome. Topoisomerase I inhibitors may, for example, be selected from camptothecin or its analogues, indomethacin, and indoxacarbazole.

[0220] In one specific embodiment, the topoisomerase-I inhibitor is camptothecin or an analogue, i.e., a compound comprising the pentacyclic basic structure of camptothecin and modified substituents that selectively result in the presence of an additional ring. Specific examples include camptothecin, topotecan, irinotecan, SN-38, belotecan, exatecan, and its derivatives deruxtecan, lurtotecan, or atitaratecan.

[0221] Exatecan

[0222] Ecinotecan, chemically named (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3′,4′:6,7]imidazo[1,2-b]quinoline-10,13(9H,15H)-dione, is a water-soluble derivative of camptothecin, and its structural formula is as follows:

[0223]

[0224] In some embodiments, the topoisomerase I inhibitor is eczemab. In some embodiments, eczemab is typically conjugated to the antibody via its NH2 group. The inventors have successfully prepared antibody-drug conjugates containing eczemab as a payload. These antibody-drug conjugates have shown significant therapeutic efficacy both in vitro and in vivo.

[0225] Connector Substructure

[0226] Regarding the antibody-drug conjugates of this application, this document describes the linker structure for conjugating an antitumor compound (e.g., eczema) to an antibody. The linker is represented by the following formula: -Q-L1-L2-.

[0227] The antibody is linked to the end of Q (opposite to the end linked to L1), and the amino group of the antitumor compound (e.g., eczetidine) is linked to the carbonyl group or C-terminus of L2.

[0228] 1. Q

[0229] Q represents the following structure: -(succinimide-3-yl-N)-(CH2)5-C(=O)- (abbreviated as -MC- in the examples).

[0230] In the above structural formula, "-(succinimide-3-yl-N)-" has the following structure:

[0231]

[0232] The above structure is linked to the antibody at position 3 and to a methylene group on the nitrogen atom at position 1. The linking to the antibody at position 3 is characterized by the formation of a thioether bond. The nitrogen atom at position 1 of this structure is bonded to the carbon atom of the methylene group present in the linker structure.

[0233] Specifically, the structure of Ab-(succinimide-3-yl-N)-(CH2)5-C(=O)-L1- is shown below:

[0234]

[0235] In this structure, "Antibody-S-" comes from antibody.

[0236] 2. L1

[0237] L1 represents a dipeptide residue with the structure -Val-Cit. This dipeptide residue can be hydrolyzed by lysosomal proteases, thereby releasing the antitumor compound into the target cell. In some embodiments, the lysosomal protease is cathepsin B.

[0238] Specifically, L1 is connected to Q via its amino or N-terminus and to L2 via its carbonyl or C-terminus. More specifically, L1 is connected to the carbonyl group of Q via its amino or N-terminus and to the amino group of L2 via its carbonyl or C-terminus.

[0239] In a preferred embodiment of this application, -Val-Cit- (also abbreviated as -VC- in the embodiment) has the following structure .

[0240] 3. L2

[0241] L2 stands for "-NH-phenyl-CH2-OC(=O)-", which is a self-destructing spacer unit that releases antitumor compounds without a separate hydrolysis step.

[0242] L2 is linked to L1 via its amino group and to eczetidine via its carbonyl group. More specifically, L2 is linked to the carbonyl group or C-terminus of L1 via its amino group and to the amino group or N-terminus of eczetidine via its carbonyl group.

[0243] In a preferred embodiment, L2 has the following structure (abbreviated as "-PABC-" or "P" in the embodiment):

[0244]

[0245] In a preferred embodiment, the linker of this application has the following structure: -(succinimide-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-Val-Cit-NH-phenyl-CH2-OC(=O)-,

[0246] in,

[0247] -(succinimide-3-yl-N)- represents the following structure:

[0248]

[0249] This group is linked to the antibody at position 3 and to a methylene group on the nitrogen atom at position 1, where the nitrogen atom of the amino group at position 1 is the linking site.

[0250] -NH-phenyl-CH2-OC(=O)- represents the following structure:

[0251] .

[0252] Linker-toxin

[0253] This application describes linker-toxin compounds that can be conjugated with antibodies. These linker-toxin compounds are represented by the following general formula: Q'-L1-L2-(NH-Exa). In some embodiments, the linker-toxin compounds of this application are intermediate products used in the preparation of the antibody-drug conjugates of this application.

[0254] In some embodiments, linker-toxin compounds were synthesized according to known chemical procedures.

[0255] The antibody reacts with the Q' end (the end opposite to the L1-linked end) to form a chemical bond. After the reaction, Q' is converted to Q.

[0256] 1. Q'

[0257] Q' corresponds to Q and includes a linker entity that can react with and conjugate with antibodies. Q' represents the following structure: (maleimide-N-yl)-(CH2)5-C(=O)-.

[0258] In the above structural formula, "(maleimide-N-yl)-" has the following structure:

[0259]

[0260] The aforementioned structure has a methylene group attached to the nitrogen atom at position 1, and can react with the cysteine ​​residue of the antibody to form a thioether bond at position 3. The nitrogen atom at position 1 of this structure is attached to the carbon atom of the methylene group present in the linker structure.

[0261] Specifically, (maleimide-N-yl)-(CH2)5-C(=O)-L1- can react with the cysteine ​​residues of the antibody to form the structure shown below:

[0262]

[0263] In this structure, "Antibody-S-" comes from antibody.

[0264] 2. L1

[0265] L1 represents a dipeptide residue with the structure -Val-Cit. This dipeptide residue can be hydrolyzed by lysosomal proteases, thereby releasing the antitumor compound into the target cell. In some embodiments, the lysosomal protease is cathepsin B.

[0266] Specifically, L1 is connected to Q' via its amino or N-terminus and to L2 via its carbonyl or C-terminus. More specifically, L1 is connected to the carbonyl group of Q' via its amino or N-terminus and to the amino group of L2 via its carbonyl or C-terminus.

[0267] In a preferred embodiment of this application, -Val-Cit- (also abbreviated as -VC- in the embodiment) has the following structure: .

[0268] 3. L2

[0269] L2 stands for "-NH-phenyl-CH2-OC(=O)-", which is a self-destructing spacer unit that releases antitumor compounds without a separate hydrolysis step.

[0270] L2 is linked to L1 via its amino group and to eczetidine via its carbonyl group. More specifically, L2 is linked to the carbonyl group or C-terminus of L1 via its amino group and to the amino group or N-terminus of eczetidine via its carbonyl group.

[0271] In a preferred embodiment, L2 has the following structure (abbreviated as "-PABC-" or "P" in the embodiments):

[0272] .

[0273] 4. -(NH-Exa)

[0274] -(NH-Exa) represents the antitumor compound eczema in antibody-drug conjugates, which has the following structure:

[0275]

[0276] In the above structure, the amino group of the antitumor compound is connected to the carbonyl group or C-terminus of L2.

[0277] In a more preferred embodiment, the linker-toxin compound of this application has the following structure: (maleimide-N-yl)-CH2CH2CH2CH2CH2-C(=O)-Val-Cit-NH-phenyl-CH2-OC(=O)-(NH-Exa) (CAS No. 2504068-28-2).

[0278] In the above-mentioned linker-toxin compounds, the (maleimide-N-yl)- group is represented by the following structure:

[0279]

[0280] In the above-mentioned linker-toxin compounds, "-NH-phenyl-CH2-OC(=O)-" is a group represented by the following structure:

[0281]

[0282] In the above linker-toxin compounds, -(NH-Exa) is a group represented by the following structure, where the nitrogen atom of the amino group at position 1 is the linking site.

[0283] .

[0284] Antibody-drug conjugates (ADCs)

[0285] With regard to the antibody-drug conjugate of this application, it comprises an anti-TROP2 antibody and an antitumor compound linked by a linker, wherein the linker and the antitumor compound are represented by the general formula -Q-L1-L2-(NH-Exa).

[0286] 1. Q

[0287] Q represents the following structural formula: -(succinimide-3-yl-N)-(CH2)5-C(=O)- (also referred to as -MC- in the examples).

[0288] In the above structural formula, "-(succinimide-3-yl-N)-" is a group represented by the following structure:

[0289]

[0290] The above structure is linked to the antibody at position 3 and to a methylene group on the nitrogen atom at position 1. The linking to the antibody at position 3 is characterized by the formation of a thioether bond. The nitrogen atom at position 1 of this structure is bonded to the carbon atom of the methylene group present in the linker structure.

[0291] Specifically, -(succinimide-3-yl-N)-(CH2)5-C(=O)-L1- is a group represented by the following structure:

[0292]

[0293] In this structure, "Antibody-S-" comes from antibody.

[0294] 2. L1

[0295] L1 represents a dipeptide residue with the structure -Val-Cit. This dipeptide residue can be hydrolyzed by lysosomal proteases, thereby releasing the antitumor compound into the target cell. In some embodiments, the lysosomal protease is cathepsin B.

[0296] Specifically, L1 is connected to Q via its amino or N-terminus and to L2 via its carbonyl or C-terminus. More specifically, L1 is connected to the carbonyl group of Q via its amino or N-terminus and to the amino group of L2 via its carbonyl or C-terminus.

[0297] In a preferred embodiment of this application, -Val-Cit- (also abbreviated as -VC- in the embodiment) has the following structure: .

[0298] 3. L2

[0299] L2 stands for "-NH-phenyl-CH2-OC(=O)-", which is a self-destructing spacer unit that releases antitumor compounds without a separate hydrolysis step.

[0300] L2 is linked to L1 via its amino group and to eczetidine via its carbonyl group. More specifically, L2 is linked to the carbonyl group or C-terminus of L1 via its amino group and to the amino group or N-terminus of eczetidine via its carbonyl group.

[0301] In a preferred embodiment, L2 has the following structure (abbreviated as "-PABC-" or "P" in the embodiment):

[0302]

[0303] 4. -(NH-Exa)

[0304] -(NH-Exa) represents the antitumor compound eczema in antibody-drug conjugates, which has the following structure:

[0305]

[0306] In the above structure, the amino group of the antitumor compound is connected to the carbonyl group or C-terminus of L2.

[0307] In a more preferred embodiment, the antibody-drug conjugate comprises an anti-TROP2 antibody linked by a linker, wherein the linker and the antitumor compound have the following structure: -(succinimide-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-Val-Cit-NH-phenyl-CH2-OC(=O)-(NH-Exa)

[0308] in,

[0309] -(succinimide-3-yl-N)- is a group represented by the following structure:

[0310]

[0311] This group is linked to the antibody at position 3 and to a methylene group on the nitrogen atom at position 1, where the nitrogen atom of the amino group at position 1 is the linking site.

[0312] -NH-phenyl-CH2-OC(=O)- is a group represented by the following structure:

[0313] ,

[0314] -(NH-Exa) is a group represented by the following structure:

[0315]

[0316] In some embodiments of this application, the anti-TROP2 antibody in the above-described antibody-drug conjugate is selected from humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibodies containing the heavy chain and / or light chain CDRs described herein. Contemplated antibodies include, for example, full-length antibodies (e.g., full-length IgG1 or IgG4), scFvs, antibody Fc fusion proteins, multispecific (e.g., bispecific) antibodies, immunoconjugates, etc. In some embodiments, the antibody is Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragments, dAb, Fd, nanobodies, biantibodies, or linear antibodies.

[0317] In a preferred embodiment of this application, the antibody in the above-mentioned antibody-drug conjugate is selected from sacrituzumab or datopotamab.

[0318] In a preferred embodiment of this application, the antibody in the antibody-drug conjugate comprises VH, wherein VH comprises: HC-CDR1, which comprises the amino acid sequence SEQ ID NO: 1; HC-CDR2, which comprises the amino acid sequence SEQ ID NO: 2; and HC-CDR3, which comprises the amino acid sequence SEQ ID NO: 3; and VL, wherein VL comprises: LC-CDR1, which comprises the amino acid sequence SEQ ID NO: 4; LC-CDR2, which comprises the amino acid sequence SEQ ID NO: 5; and LC-CDR3, which comprises the amino acid sequence SEQ ID NO: 6.

[0319] In a preferred embodiment of this application, the antibody in the antibody-drug conjugate comprises: VH, the VH comprising the amino acid sequence SEQ ID NO: 7 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 7; and VL, the VL comprising the amino acid sequence SEQ ID NO: 8 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 8.

[0320] In a more preferred embodiment of this application, the antibody in the antibody-drug conjugate comprises: a heavy chain comprising the amino acid sequence SEQ ID NO: 9; and a light chain comprising the amino acid sequence SEQ ID NO: 10.

[0321] In other embodiments of this application, the anti-TROP2 antibody in the antibody-drug conjugate comprises: VH, the VH comprising the amino acid sequence SEQ ID NO: 11 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 11; and VL, the VL comprising the amino acid sequence SEQ ID NO: 12 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 12.

[0322] In a more preferred embodiment of this application, the anti-TROP2 antibody in the antibody-drug conjugate comprises: a heavy chain comprising the amino acid sequence SEQ ID NO: 13; and a light chain comprising the amino acid sequence SEQ ID NO: 14.

[0323] The antibody-drug conjugates of this application can be prepared by any method known to those skilled in the art. In a preferred embodiment according to this application, the antibody-drug conjugates can be prepared by coupling a cysteine ​​residue in the antibody to an electrophilic group of the linker-toxin moiety, preferably by coupling a cysteine ​​residue present on the antibody to a maleimide moiety present on the linker-toxin moiety.

[0324] Maleimide-cysteine ​​coupling can be performed using methods known to those skilled in the art.

[0325] Typically, antibodies contain almost no free active cysteine ​​thiols that can bind to the drug-linker moiety. Most cysteine ​​thiols in antibodies exist as disulfide bonds and must be reduced using reducing agents such as dithiothreitol (DTT) or TCEP under partial or complete reduction conditions. The drug loading (drug / antibody ratio) of an ADC can be controlled in a variety of ways, including: (i) limiting the molar excess of the linker-toxin intermediate or linker reagent relative to the antibody, (ii) limiting the coupling reaction time or temperature, and (iii) partial or limited reduction conditions for cysteine ​​thiols modification.

[0326] The disulfide bond structure of human IgG is now well defined (see Liu and May, mAbs 4 (2012):17-23). ​​Indeed, the disulfide bond structures of the four human IgG subclasses (IgG 1, IgG 2, IgG 3, and IgG 4) share many similarities as well as some differences. All IgG subclasses contain 12 intrachain disulfide bonds, but the interchain disulfide bonds formed between the heavy and light chains differ. Each intrachain disulfide bond is associated with an IgG domain, namely the variable region (VL and VH) and the constant region (CL, CH 1, CH 2, and CH 3). The two heavy chains are connected in their hinge regions by a varying number of disulfide bonds: IgG 1 and IgG 4 have 2 disulfide bonds, IgG 2 has 4 disulfide bonds, and IgG 3 has 11 disulfide bonds. In IgG 1, the heavy and light chains are linked by disulfide bonds located between the last cysteine ​​residue of the light chain and the fifth cysteine ​​residue of the heavy chain. In other subclasses, IgG 2, IgG 3, and IgG 4, the light chain is linked by a disulfide bond between the terminal cysteine ​​residue of the light chain and the third cysteine ​​residue at the VH region and CH1 interface of the heavy chain. Besides these classic structures, disulfide conformations of IgG 2 and IgG 4 have been reported (see Liu and May, mAbs 4 (2012): 17-23). ​​Interchain disulfide bonds are highly exposed to the solvent environment and are therefore more active than intrachain disulfide bonds, which are buried in the antiparallel β-sheet structure within each domain and are not exposed to the solvent. For these reasons, regardless of antibody subtype, the exposed cysteine ​​residues between chains will couple after mild reduction. Therefore, theoretically, each interchain disulfide bond can form two conjugated sites.

[0327] Additional nucleophilic groups can be introduced into the antibody by reacting lysine with a 2-iminothionine (Trust's) reagent to convert the amino group into a thiol group. Reactive thiol groups can also be introduced into the antibody (or fragments thereof) by modifying one, two, three, four, or more cysteine ​​residues (e.g., preparing mutant antibodies containing one or more non-natural cysteine ​​amino acid residues). US 7521541 discloses a method for modifying antibodies by introducing reactive cysteine ​​amino acids.

[0328] Cysteine ​​amino acids can be engineered at the reaction sites of antibodies without forming intramolecular or intermolecular disulfide bonds (Junutula, et al, 2008b Nature Biotech., 26(8): 925-). Engineered cysteine ​​thiols can react with linker reagents or linker-toxin reagents containing thiol-reactive electrophilic groups (such as maleimide or α-haloamide) to form ADCs with cysteine-engineered antibodies and drug moieties. Therefore, the position of the drug moieties can be designed, controlled, and determined. Drug loading is controllable because engineered cysteine ​​thiol groups typically react efficiently with thiol-reactive linker reagents or linker-toxin reagents. By modifying IgG antibodies, cysteine ​​amino acids are introduced through substitution at a single site on the heavy or light chain, resulting in two new cysteine ​​sites on symmetrical antibodies. Drug loading close to 2 can be achieved using nearly homogeneous conjugate ADCs (homogeneity).

[0329] When multiple nucleophilic or electrophilic groups of an antibody react with a linker-toxin intermediate or with a linker reagent, and then with a toxin moiety reagent, the resulting product is a mixture of ADC compounds in which the distribution of the toxin moiety attached to the antibody is polymorphic, such as 1, 2, 3, etc. Liquid chromatography, such as polymer reversed-phase (PLRP) and hydrophobic interaction (HIC), can separate the compounds in the mixture by drug loading value. Formulations of ADCs with a single drug loading value (p) can be separated, but these single-loading ADCs may still be heterogeneous mixtures because the toxin moiety can attach to different sites on the antibody via the linker.

[0330] For some antibody-drug conjugates, the drug loading may be limited by the number of attachment sites on the antibody. High drug loading (e.g., drug loading > 5) can lead to aggregation, insolubility, toxicity, or loss of cell permeability in some antibody-drug conjugates. Typically, in the conjugation reaction, the number of drug groups conjugated to the antibody is less than the theoretical maximum.

[0331] Drug loading (also known as drug-antibody ratio (DAR)) refers to the average amount of drug bound to each antibody.

[0332] For IgG1 and IgG4 isotype antibodies, the drug binds to cysteine ​​after partial antibody reduction. The drug loading may be 1 to 8 drugs per antibody, i.e., 1, 2, 3, 4, 5, 6, 7 and 8 drug groups covalently linked to the antibody.

[0333] For IgG 2 isotype antibodies, the drug binds to cysteine ​​after partial antibody reduction. The drug loading may be 1 to 12 drugs per antibody, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 drug groups covalently linked to the antibody.

[0334] An ADC consists of a series of cell-binding agents (e.g., antibodies) conjugated with 1 to 8 or 1 to 12 drugs.

[0335] The average amount of drug in each antibody in an ADC formulation prepared by coupling reaction can be characterized by conventional methods, such as UV detection, reversed-phase HPLC, HIC, mass spectrometry, ELISA assay, and electrophoresis.

[0336] In some embodiments, the antibody-drug conjugate comprises any antibody, any linker, or any linker-toxin compound described herein.

[0337] In a preferred embodiment, this application provides a method for conjugating a toxin to an antibody via a special linker portion. The antibody-drug conjugate reported herein ultimately possesses the following characteristics: (i) uniform conjugation, (ii) improved hydrophilicity of the resulting ADC, (iii) excellent linker-toxin plasma stability, (iv) effective in vivo activity against breast cancer and gastric cancer models, and (v) strong in vitro cytotoxicity against cancer cells.

[0338] Although not exemplified or emphasized in the embodiments of this application, other ADCs that include the linker-toxin disclosed in this disclosure and are conjugated with antibodies targeting other targets (such as anti-FRα (folate receptor α) antibodies, etc.) are still worth developing and investigating:

[0339] For example, an antibody-drug conjugate comprising an anti-FRα antibody and an antitumor compound linked by a linker, wherein the linker and the antitumor compound have the structure -(succinimide-3-yl-N)-CH2CH2CH2CH2CH2-C(═O)-Val-Cit-NH-phenyl-CH2-OC(═O)-(NH-Exa), and the antibody comprising: VH, the VH comprising the amino acid sequence SEQ ID NO: 15 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 15; and VL, the VL comprising the amino acid sequence SEQ ID NO: 16 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 16. More preferably, the antibody comprises: a heavy chain, the heavy chain comprising the amino acid sequence SEQ ID NO: 17; and a light chain, the light chain comprising the amino acid sequence SEQ ID NO: 18. In another example, an antibody-drug conjugate comprises an anti-FRα antibody and an antitumor compound linked by a linker, wherein the linker and the antitumor compound have the structure -(succinimide-3-yl-N)-CH2CH2CH2CH2CH2-C(═O)-Val-Cit-NH-phenyl-CH2-OC(═O)-(NH-Exa), and the antibody comprises: VH, the VH comprising the amino acid sequence SEQ ID NO: 19 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 19; and VL, the VL comprising the amino acid sequence SEQ ID NO: 20 or a variant thereof, the variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 20. More preferably, the antibody comprises: a heavy chain, the heavy chain comprising the amino acid sequence SEQ ID NO: 21; and a light chain, the light chain comprising the amino acid sequence SEQ ID NO: 22.

[0340] Production methods

[0341] Next, representative manufacturing methods for the antibody-drug conjugates or their intermediates of this application will be explained. Meanwhile, these compounds will be described below using the numbers or letters shown in each reaction scheme. Specifically, they will be referred to as "compound of formula (a)," "compound (a)," or similar names.

[0342] In a representative example, the antibody-drug conjugate of this application can be produced by the process shown in Scheme 1.

[0343] Option 1:

[0344]

[0345] Procedure 1: Synthesis of Q'-L1-L2-PNP (Compound 1).

[0346] Process 2: Compound 1 is contacted with eczema to generate a linker-toxin compound with the structural formula Q'-L1-L2-(NH-Exa) (compound 2, also known as linker-toxin).

[0347] Process 3: The compound 2 obtained in process 2 (also known as the linker-toxin) is contacted with the antibody to produce an antibody-drug conjugate.

[0348] Process 1

[0349] In this process, intermediate compound Q'-L1-L2-PNP (compound 1) was synthesized, which is used as one of the starting materials for the preparation of linker toxins in this application.

[0350] 1. Q'

[0351] Q' corresponds to Q and includes a linker entity that can react with and conjugate with antibodies. Q' represents the following structure: (maleimide-N-yl)-(CH2)5-C(=O)-.

[0352] In the above structural formula, "(maleimide-N-yl)-" has the following structure:

[0353]

[0354] The aforementioned structure has a methylene group attached to the nitrogen atom at position 1, and can react with the cysteine ​​residue of the antibody to form a thioether bond at position 3. The nitrogen atom at position 1 of this structure is attached to the carbon atom of the methylene group present in the linker structure.

[0355] Specifically, (maleimide-N-yl)-(CH2)5-C(=O)-L1- can react with the cysteine ​​residues of the antibody to form the structure shown below:

[0356]

[0357] In this structure, "Antibody-S-" comes from antibody.

[0358] 2. L1

[0359] L1 represents a dipeptide residue with the structure -Val-Cit. This dipeptide residue can be hydrolyzed by lysosomal proteases, thereby releasing the antitumor compound into the target cell. In some embodiments, the lysosomal protease is cathepsin B.

[0360] Specifically, L1 is connected to Q' via its amino or N-terminus and to L2 via its carbonyl or C-terminus. More specifically, L1 is connected to the carbonyl group of Q' via its amino or N-terminus and to the amino group of L2 via its carbonyl or C-terminus.

[0361] In a preferred embodiment of this application, -Val-Cit- (also abbreviated as -VC- in the embodiment) has the following structure: .

[0362] 3. L2

[0363] L2 stands for "-NH-phenyl-CH2-OC(=O)-", which is a self-destructing spacer unit that releases antitumor compounds without a separate hydrolysis step.

[0364] L2 is linked to L1 via its amino group and to eczetidine via its carbonyl group. More specifically, L2 is linked to the carbonyl group or C-terminus of L1 via its amino group and to the amino group or N-terminus of eczetidine via its carbonyl group.

[0365] In a preferred embodiment, L2 has the following structure (abbreviated as "-PABC-" or "P" in the embodiments):

[0366] .

[0367] In the above compounds, PNP is a group represented by the structure "-O-phenyl-NO2", or .

[0368] In a more preferred embodiment, compound 1 of this application has the following structure: (maleimide-N-yl)-CH2CH2CH2CH2CH2-C(=O)-Val-Cit-NH-phenyl-CH2-OC(=O)-PNP,

[0369] In the above-mentioned linker-toxin compounds, the (maleimide-N-yl)- group is represented by the following structure:

[0370]

[0371] In the above linker-toxin compounds, "-NH-phenyl-CH2-OC(=O)-" is a group represented by the following structure:

[0372]

[0373] In a more preferred embodiment of this application, the method of process 1 is well known in the art, see, for example, Gene M. Dubowchik et al., Bioconjugate Chem. 2002, 13, 855-869, or USpatent No. US6214345B1, the entire contents of which are incorporated herein by reference.

[0374] Specifically, in a representative embodiment, compound 1 can be prepared according to scheme 2 below:

[0375]

[0376]

[0377] Although the preparation method of compound 1 is well known and exemplified above, the compound is also commercially available. Therefore, in a more preferred embodiment of this application, compound 1 can be obtained from a commercial supplier, such as Selleckchem, product number S6832.

[0378] Process 2

[0379] In this process, the linker-toxin (i.e., compound 2) of this application can be prepared and used in the production of antibody-drug conjugates.

[0380] For example, under suitable conditions, compound 1 is contacted with eczetazone to generate compound 2. The method of process 2 is well known in the art, see, for example, Weng W et al., Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13(4):950-973, the entire contents of which are incorporated herein by reference. Specifically, in a preferred embodiment, compound 1, HOBt (hydroxybenzotriazole) and pyridine are added to an eczetazone mesylate solution. The reaction mixture is stirred at room temperature for 24 hours. The resulting residue is purified by silica gel column chromatography with dichloromethane:methanol as eluent to obtain purified compound 2.

[0381] For compound 2 described in this application, in some embodiments, the compound has the following structure: (maleimide-N-yl)-CH2CH2CH2CH2CH2-C(=O)-Val-Cit-NH-phenyl-CH2-OC(=O)-(NH-Exa) (CAS No. 2504068-28-2).

[0382] Wherein, (maleimide-N-yl)- is a group represented by the following structure:

[0383]

[0384] "-NH-phenyl-CH2-OC(=O)-" is a group represented by the following structure:

[0385]

[0386] In the above linker-toxin compounds, -(NH-Exa) is a group with the following structure, where the nitrogen atom of the amino group at position 1 serves as the binding site.

[0387] .

[0388] The preparation method of compound 2 is well known and has been exemplified above, but the compound is also commercially available. Therefore, in a more preferred embodiment of this application, compound 2 can be obtained from a commercial supplier, for example, Monmouth, NJ, product number HY-145929, lot number 151333.

[0389] Process 3

[0390] In this process, antibody-drug conjugates can be produced by reacting compound 2 obtained in process 2 with an antibody containing a thiol group.

[0391] In some embodiments, the antibody is selected from humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibodies comprising the heavy chain and / or light chain CDRs discussed herein. Contemplated antibodies include, for example, full-length antibodies (e.g., full-length IgG1 or IgG4), scFvs, antibody Fc fusion proteins, multispecific (e.g., bispecific) antibodies, immunoconjugates, etc. In some embodiments, the antibody is Fab, aFab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragments, dAb, Fd, nanobodies, biantibodies, or linear antibodies.

[0392] In one embodiment, the antibody is selected from anti-TROP-2 antibodies.

[0393] In a preferred embodiment, the antibody is selected from Sacituzumab or Datopotamab.

[0394] In a preferred embodiment, the antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO: 1; HC-CDR2, which contains the amino acid sequence SEQ ID NO: 2; and HC-CDR3, which contains the amino acid sequence SEQ ID NO: 3; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO: 4; LC-CDR2, which contains the amino acid sequence SEQ ID NO: 5; and LC-CDR3, which contains the amino acid sequence SEQ ID NO: 6.

[0395] In a preferred embodiment, the antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO: 7 or a variant thereof, said variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 7; and V L The V L It contains the amino acid sequence SEQ ID NO: 8 or a variant thereof, said variant having at least about 90% sequence identity with the amino acid sequence SEQ ID NO: 8.

[0396] In a more preferred embodiment, the antibody comprises: a heavy chain comprising the amino acid sequence SEQ ID NO: 9; and a light chain comprising the amino acid sequence SEQ ID NO: 10.

[0397] The antibody-drug conjugates of this application can be prepared by any method known to those skilled in the art (see, for example, Ting Shao et al., Signal Transduction and Targeted Therapy (2020) 5:132; US Pat. NO. 10,195,288, the entire contents of which are incorporated herein by reference).

[0398] In a preferred embodiment of this application, the antibody-drug conjugate of this application can be prepared by coupling a cysteine ​​residue on the antibody to an electrophilic group of the linker-toxin moiety, preferably by coupling a cysteine ​​residue on the antibody to a maleimide moiety of the linker-toxin moiety.

[0399] Antibodies containing thiol groups can be obtained by methods known in the art (Hermanson, GT, Bioconjugate, pp. 56-136, pp. 456-493, Academic Press (1996)). Examples include: the reaction of the antibody's amino group with Traut's reagent; the reaction of the antibody's amino group with N-succinimide S-acetylthioalkyl ester followed by a reaction with hydroxylamine; the reaction with N-succinimide 3-(pyridinedithio)propionate followed by a reaction with a reducing agent; and the reaction of the antibody with reducing agents such as dithiothreitol, 2-mercaptoethanol, and tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP) to reduce the disulfide bonds in the hinge portion of the antibody to form thiol groups, but not limited thereto.

[0400] In a preferred embodiment, specifically, 0.3 to 3 molar equivalents of TCEP are used as a reducing agent for the disulfide bonds in the hinge moiety of the antibody, and the antibody is reacted with a buffer solution containing a chelating agent to obtain an antibody with partially or completely reduced disulfide bonds in the hinge moiety. Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA). Their concentration range is 1 mM to 20 mM. Examples of buffer solutions that can be used include solutions of sodium phosphate, sodium borate, or sodium acetate. Specifically, antibodies with partially or completely reduced thiol groups can be obtained by reacting the antibody with TCEP at 4 °C–37 °C for 1–4 hours.

[0401] The linker-toxin can be coupled to the antibody via a thioether bond through the reaction of the thiol group with compound 3, a method well known in the art (see, for example, Dubowchik et al, Bioconjugate Chem. 2002, 13:855-869).

[0402] In one exemplary embodiment, using 2 to 20 molar equivalents of compound 3 per saturated antibody, an antibody-drug conjugate covalently binding 2 to 8 drug molecules per saturated antibody can be prepared. Specifically, the reaction is carried out simply by adding a solution containing compound 3 to a buffer solution containing an antibody having thiol groups for the reaction. Examples of buffer solutions that can be used herein include sodium acetate, sodium phosphate, and sodium borate solutions, with the reaction at a pH of 5 to 9, more preferably, at a pH near 7. Examples of solvents used to dissolve compound 3 include organic solvents such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), and N-methyl-2-pyrrolidone (NMP).

[0403] The reaction can be carried out by adding an organic solvent solution containing compound 3 at a concentration of 1-20% v / v to a buffer solution containing an antibody with a thiol group. The reaction temperature is 0-37 °C, more preferably 10-25 °C, and the reaction time is 0.5-2 hours. The reaction can be terminated by inactivating unreacted compound 3 with a thiol-containing reagent. Examples of thiol-containing reagents include cysteine ​​and N-acetyl-L-cysteine ​​(NAC). More specifically, the reaction can be terminated by adding 1 to 2 molar equivalents of NAC to the compound 3 used and incubating at room temperature for 10 to 30 minutes.

[0404] The prepared antibody-drug conjugates can be concentrated, buffer-replaced, purified, and the antibody concentration and the average number of drug molecules conjugated to each antibody can be determined. All of these procedures are well known in the art.

[0405] Pharmaceutical Composition

[0406] Another aspect of this application is a pharmaceutical composition comprising an antibody-drug conjugate according to this application and a pharmaceutically acceptable carrier and / or excipient.

[0407] Examples of suitable carriers and excipients for formulating antibody-drug conjugates include physiological saline and aqueous buffer solutions, and are well known in the art. Typically, the pharmaceutical composition is suitable for parenteral administration, such as for subcutaneous injection, intramuscular injection, intravenous injection, or infusion.

[0408] According to this application, the ADC can be in the form of a pharmaceutically acceptable salt.

[0409] In this application, "pharmaceutically acceptable" means that it can be used to prepare pharmaceutical compositions, is generally safe, non-toxic, and has no adverse effects on biology or otherwise, and can be used for veterinary and human pharmaceutical purposes.

[0410] The substances used in the pharmaceutical compositions containing antibody-drug conjugates in this application may be appropriately selected and used from pharmaceutical additives or analogs commonly used in the art, depending on the dosage or administration concentration.

[0411] The antibody-drug conjugate of this application can be administered as a pharmaceutical composition containing at least one pharmaceutically suitable ingredient.

[0412] For example, the pharmaceutical compositions described above typically contain at least one drug carrier (e.g., a sterile liquid). Examples include water and oil (animal-derived petroleum and oils, plant-derived or synthetic-derived oils (oils can be, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc.)). Water is a more common carrier when the pharmaceutical compositions described above are administered intravenously. Aqueous saline solutions, glucose solutions, and glycerol solutions can also be used as liquid carriers, particularly for injections. Suitable drug carriers are known in the art. If desired, the compositions may also contain trace amounts of a humectant, emulsifier, or pH buffer. Examples of suitable drug carriers are disclosed by EW Martin in Remremington's Pharmaceutical Sciences. The formulations correspond to the administration regimen.

[0413] Various delivery systems are known and can be used to administer the antibody-drug conjugate of the present invention. Examples of routes of administration include, but are not limited to, intradermal injection, intramuscular injection, intraperitoneal injection, intravenous injection, and subcutaneous injection. For example, administration may be by injection or bolus. According to a specific preferred embodiment, the antibody-drug conjugate is administered by injection. Parenteral administration is a preferred route of administration.

[0414] According to a representative embodiment, the pharmaceutical composition is defined as a pharmaceutical composition suitable for intravenous injection into humans, following conventional methods. Compositions for intravenous administration are typically sterile isotonic buffer solutions. If desired, the drug may contain a solubilizer and a local anesthetic to reduce pain at the injection site (e.g., lidocaine). Generally, the above-mentioned components can be provided individually, in the form of lyophilized powder or anhydrous concentrate, in containers sealed in ampoules or pouches containing a specified amount of the active ingredient; or they can be mixtures in single-dose formulations. When injection is required, an injection bottle containing sterile pharmaceutical-grade water or physiological saline can be used for injection. When the drug is administered by injection, an ampoule of sterile water for injection or physiological saline can be provided to mix the above-mentioned components together before administration.

[0415] The pharmaceutical composition of this application may be a pharmaceutical composition containing only the antibody-drug conjugate of this application, or a pharmaceutical composition containing the antibody-drug conjugate and at least one anticancer drug other than the conjugate. The antibody-drug conjugate of this invention can be administered together with other anticancer drugs. The anticancer effect can be enhanced accordingly. Another anticancer drug for such purposes can be administered to the patient simultaneously with, alone or subsequently with, the antibody-drug conjugate, and the dosing interval of each drug can be varied. Examples of anticancer drugs include albumin-bound paclitaxel, carboplatin, cisplatin, gemcitabine, irinotecan (CPT-11), paclitaxel, pemetrexed, sorafenib, vinorelbine, drugs described in International Publication No. WO 2003 / 038043, LH-RH analogs (leuprorelin, goserelin, etc.), estradiol phosphate, estrogen antagonists (tamoxifen, raloxifene, etc.), and aromatase inhibitors (anastrozole, letrozole, exemestane, etc.), as long as it is a drug with antitumor activity.

[0416] Pharmaceutical compositions can be formulated into lyophilized or liquid formulations having the desired composition and purity. When formulated as lyophilized formulations, they can be formulations containing suitable pharmaceutical additives commonly used in the art. Furthermore, for liquid formulations, they can be formulated as liquid formulations containing various pharmaceutical additives commonly used in the art.

[0417] The composition and concentration of the pharmaceutical composition may vary depending on the method of administration. However, the antibody-drug conjugate contained in the pharmaceutical composition of this application has a high affinity for the antigen, and can exhibit a pharmaceutical effect even at very small doses. That is, when the dissociation constant (i.e., Kd value) of the antibody-drug conjugate to the antigen is relatively low, its affinity is high (= lower Kd value). Therefore, in order to determine the dose of the antibody-drug conjugate, the dose can be determined based on the affinity between the antibody-drug conjugate and the antigen. When the antibody-drug conjugate of this application is administered to humans, for example, about 0.001-100 mg / kg can be administered as a single dose or in divided doses, with intervals between doses ranging from 1 to 180 days.

[0418] A "pharmacologically acceptable salt" of a compound is a pharmaceutically acceptable salt as defined herein and which has the desired pharmacological activity of the parent compound.

[0419] Pharmaceutically acceptable salts, especially including:

[0420] (1) Pharmaceutically acceptable acid addition salts formed with pharmaceutically acceptable inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, etc.), or pharmaceutically acceptable acid addition salts formed with pharmaceutically acceptable organic acids (such as acetic acid, trifluoroacetic acid, propionic acid, succinic acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, glutamic acid, benzoic acid, salicylic acid, toluenesulfonic acid, methanesulfonic acid, stearic acid, lactic acid, etc.); and

[0421] (2) Pharmaceutically acceptable base addition salts formed when the acid protons in the parent compound are replaced by metal ions (such as alkali metal ions, alkaline earth metal ions or aluminum ions); or pharmaceutically acceptable base addition salts formed when coordinated with pharmaceutically acceptable organic bases (such as lysine, arginine, etc.); or pharmaceutically acceptable base addition salts formed when coordinated with pharmaceutically acceptable inorganic bases (such as sodium hydroxide, potassium hydroxide, calcium hydroxide, etc.).

[0422] These salts can be prepared using conventional chemical methods by reacting compounds containing base or acid functional groups described in this application with the corresponding acids or bases.

[0423] Medical Use

[0424] The antibody-drug conjugates described in this application are particularly suitable for treating cancer. Therefore, this application also relates to the use of the antibody-drug conjugates in pharmaceuticals. On the other hand, this application also relates to a method of treating a subject in need, the method comprising administering the antibody-drug conjugates described in this application to the subject. The method in the present aspect can also be described as follows: the antibody-drug conjugates of this application can be used for treatment, particularly for treating a subject in need. The method in the present aspect can also be described as follows: the antibody-drug conjugates of this application are used to prepare a pharmaceutical product. In this document, a therapeutically effective amount of the antibody-drug conjugate is typically used for administration.

[0425] This application also relates to a method for treating a specific disease in a subject with this need, comprising administering an antibody-drug conjugate as defined above in this application. Specific diseases may be selected from cancer and autoimmune diseases, with cancer being preferred. Subjects with this need are typically cancer patients. The use of antibody-drug conjugates in such treatment is well known, particularly in the field of cancer treatment, and the antibody-drug conjugate according to this application is particularly suitable in this regard. In the method according to this aspect, the antibody-drug conjugate is typically administered in a therapeutically effective amount. The present aspect of this application may also be expressed as the use of the antibody-drug conjugate of this application for treating a specific disease in a subject with this need, preferably for treating cancer. In other words, this aspect relates to the use of the antibody-drug conjugate of this application in the preparation of a medicament or pharmaceutical composition for treating a specific disease in a subject with this need, preferably for treating cancer. The antibody-drug conjugate of this application may preferably be administered to mammals, but more preferably to humans.

[0426] Cancers that require prevention and / or treatment can be any kind of cancer, where the term "cancer or tumor" is used in this article to refer to proliferative diseases.

[0427] The cancer may preferably be selected from target-associated cancers, which include all or part of the tumor cells that express or overexpress a target on their surface.

[0428] In one embodiment, the cancer is a HER2-positive cancer, such as HER2-positive breast cancer, HER2-positive gastric cancer, HER2-positive colon cancer, HER2-positive lung cancer, HER2-positive pancreatic cancer, HER2-positive urothelial carcinoma, HER2-positive brain cancer, or HER2-positive ovarian cancer. Therefore, in one embodiment, the patient is HER2-positive.

[0429] In one embodiment, the cancer is a TROP2-positive cancer, such as breast cancer, ovarian cancer, cervical cancer, endometrial cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, esophageal cancer, bladder cancer, kidney cancer, pancreatic cancer, thyroid cancer, and head and neck cancer. ADCs may be particularly useful for treating cancers that have developed resistance to one or more standard anticancer therapies, such as colorectal cancer, pancreatic ductal carcinoma, triple-negative breast cancer, or small cell lung cancer.

[0430] In one embodiment, the cancer is FRα-positive cancer. FRα overexpression is present in 90% of epithelial ovarian cancers, as well as many other cancers, including endometrial cancer, renal cell carcinoma, lung cancer, mesothelioma, breast cancer, brain cancer, and myeloid leukemia, while most normal tissues express it at negligible levels (Coney et al., 1991, Cancer Res. 51:6125-6132). In some embodiments, the cancer cells are folate receptor α (FRα)-positive lymphomas or folate receptor α (FRα)-positive leukemia cells. In some embodiments, the cancer is ovarian cancer, lung cancer, uterine cancer, choriocarcinoma of the testis, ependymoma, mesothelioma, breast cancer, colon cancer, or renal cell carcinoma.

[0431] Depending on the stage and severity of the disease, the pharmaceutical composition or antibody-drug conjugate of this application may be administered once or multiple times to a subject in need, particularly a human subject, at a therapeutically effective dose. For example, it may be administered once or multiple times daily, every other day, twice a week, or once a week for an appropriate period of time, such as at least one week, or at least one month.

[0432] Antibody-drug conjugates can be administered alone or in combination with other active agents, which may be selected from (chemotherapeutic agents, such as antimetabolites, alkylating agents, intercalating agents, or antimitotic agents), inhibitors of specific kinases, such as tyrosine kinase inhibitors, serine / threonine kinase inhibitors, or inositol phosphokinase inhibitors, immunotherapeutic compounds, such as immune checkpoint inhibitors, CAR-T cells, therapeutic vaccines, or oncolytic viruses.

[0433] Reagent test kit

[0434] Therefore, this application also relates to a kit comprising at least i) the antibody-drug conjugate and / or pharmaceutical composition described in this application, and ii) a syringe, vial, or ampoule containing the antibody-drug conjugate and / or the pharmaceutical composition.

[0435] Their administration patterns, dosages, and optimal drug forms can be determined based on criteria typically considered when developing a treatment regimen suitable for a patient, such as the patient's age or weight, the severity of their overall condition, tolerance to treatment, and known side effects.

[0436] Exemplary kits may contain at least one anti-Trop-2 ADC, anti-HER2 ADC, or anti-FRα ADC as described herein. If the composition containing the administration component is not formulated for administration via the digestive tract, such as oral delivery, a device capable of delivering the kit components via some other route is required. One type of device for such parenteral delivery is a syringe for injecting the composition into the subject's body. Inhalation devices may also be used, and in some embodiments, the anti-Trop-2 ADC, anti-HER2 ADC, or anti-FRα ADC may be provided as a pre-filled syringe or auto-injection pen containing a sterile liquid or lyophilized formulation (e.g., Kivitz et al., Clin. Ther. 2006, 28:1619-29).

[0437] The kit components can be packaged as a whole or aliquoted into two or more containers. In some embodiments, the containers may be vials containing sterile lyophilized formulations suitable for reconstitution. The kit may also contain one or more buffer solutions suitable for reconstitution and / or dilution of other reagents. Other optional containers include, but are not limited to, bags, trays, boxes, tubes, etc. The kit components can be sterilely packaged and stored within the containers. An instruction manual may also be included as an integral part of the kit.

[0438] Example

[0439] Various features and embodiments of this disclosure are illustrated in the following representative examples, which are intended to be illustrative rather than restrictive. Those skilled in the art will understand that the specific examples are for illustrative purposes only and are described more fully in the following claims. Each embodiment and feature described in this application should be understood to be interchangeable and can be combined with each embodiment included therein.

[0440] Example 1: Preparation of Antibody

[0441] Anti-Trop2 antibody (with the same sequence as sacrituzumab, also known as hRS7)

[0442] The hRS 7 antibody was produced in accordance with the description in US Patent No. 7,238,785, the entire contents of which are incorporated herein by reference.

[0443] hRS7 antibody is a humanized IgG1κ antibody targeting Trop2 (trophoblast antigen 2). The amino acid sequence of hRS7 antibody is shown in Table 2.

[0444] Table 2

[0445]

[0446] Example 2: Preparation of Antibody-Drug Conjugates (ADCs)

[0447] The preparation of the ADC involves three unique steps that have been reported elsewhere (see, for example, Ting Shao et al., Signal Transduction and Targeted Therapy (2020) 5:132; USPat. NO. 10,195,288) and have been modified specifically for this particular linker-toxin.

[0448] Fabrication of hRS7 ADC

[0449] Preparation of hRS7-maleimide hexanoic acid-Val-Cit-PABC-Exatecan (hRS7-MC-VCP-Exa) ADC, with the structural formula "hRS7-(succinimide-3-yl-N)-CH2CH2CH2CH2CH2-C(═O)-Val-Cit-NH-phenyl-CH2-OC(=O)-(NH-Exa)"

[0450] 1) Antibody reduction The antibody solution was buffer-displaced with 10 mM pH 5.0 acetate buffer. The protein concentration of the antibody solution after displacement was determined at 280 nm using a NanoDrop spectrophotometer, with an appropriate extinction coefficient used to ensure the protein concentration was within the range of 1-10 mg / mL. A 10 mM Tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP) aqueous solution was prepared separately. 26.6 µL of 10 mM TCEP was added to 0.5 mL of buffer-displaced hRS7 solution (protein concentration 9.83 mg / mL) at a molar ratio of 8:1 (TCEP:hRS7). The reduction reaction was carried out precisely in a 37°C water bath for 2 hours. After reduction, the test tubes were cooled to room temperature in an ice bath.

[0451] 2) Linker-toxin-antibody conjugation: The linker-toxin (i.e., MC-VCP-Exa) was purchased from a commercial source (product number HY-145929, lot number 151333, Monmouth, NJ, CAS number: 2504068-28-2), and its structural formula is as follows (also known as MC-VC-PABC-Exa): (maleimide-N-yl)-CH2CH2CH2CH2CH2-C(═O)-Val-Cit-NH-phenyl-CH2-OC(=O)-(NH-Exa).

[0452] After weighing the linker-toxin, place it into a plastic tube and add an appropriate amount of dimethylformamide (DMF) to achieve a final linker-toxin concentration of approximately 5-10 mM. Add 20.8 µL (8.0 mM) of MC-VCP-Exa DMF solution to 0.25 mL of reducing antibody solution at a molar ratio of linker-toxin to hRS7 antibody of 10:1. Incubate the reagent tubes overnight (17 hours) and monitor the coupling reaction progress using reversed-phase high-performance liquid chromatography (RP-HPLC).

[0453] 3) purification ADC can be purified via buffer exchange or via a protein A affinity column. When using buffer exchange, a suitable protein concentrator is used, typically requiring 5 buffer exchange cycles, with each cycle reducing the volume by approximately 10-fold. If using a protein A column, the column is activated with 1×PBS. The ADC sample is then loaded, washed with 1×PBS, followed by washing with 1×PBS containing 0.5 M sodium chloride solution, and then eluted with 10 mM citric acid (pH 3.0). The eluent is further buffer exchanged with 10 mM pH 5.0 acetate buffer.

[0454] Drug-Antibody Ratio (DAR) Assay: DAR was determined using the RP-HPLC method reported by Jun Ouyang (Antibody-Drug Conjugates, Methods in Molecular Biology, Vol 1045, Laurent Ducry (ed.), pp 275-283). In brief, 50 μL of purified ADC was transferred to a test tube at a protein concentration of 1-5 mg / mL. Then, dithiothreitol (DTT) solution (5 µL, 0.5 M) and Tris buffer (1 µL, 1 M pH 8.0) were added. The tubes were incubated in a 37 °C water bath for 25 min. The solution was then injected into an HPLC column for analysis. The weighted average DAR was obtained by calculating the percentage of peak area for each specified peak.

[0455] Physicochemical characterization: The final ADC protein concentration was measured to be 5.76 mg / mL at 280 nm using a NanoDrop One spectrophotometer, with a total volume of 0.3 mL. The DAR was measured to be 7.52 using RP-HPLC, indicating a yield of 70%.

[0456] RP-HPLC analysis was performed under the following conditions to examine the coupling reaction process and for DAR analysis.

[0457] HPLC System: Agilent 1100 equipped with a diode array detector (DAD)

[0458] Detection wavelengths: 280 nm and 380 nm

[0459] Column: Agilent Zorbax 300SB CN, 3.5 µm, 3.0 × 150 mm or Zorbax 300SBC8, 3.5 µm, 3.0 × 150 mm

[0460] Column temperature: 65 °C

[0461] Mobile phase A: An aqueous solution containing 0.1% trifluoroacetic acid (TFA).

[0462] Mobile phase B: Acetonitrile solution containing 0.1% trifluoroacetic acid (TFA)

[0463] Flow rate: 0.8 mL / min

[0464] Gradient program: 20-30% B (0-2 minutes), 30-60% B (2-20 minutes), 60-80% B (20-22 minutes), 80-80% B (22-24 minutes), 80-20% B (24-25 minutes), 20-20% B (25-26 minutes)

[0465] Sample injection volume: 5-10 µL

[0466] Reference ADC: Trodelvy® (hRS7-CL2A-SN-38)

[0467] Trodelvy® (sacituzumab govitecan-hziy) is a combination of three parts: an hRS7 antibody and a cytotoxin SN-38 linked by the linker CL2A. The Trodelvy® used in the experiment was purchased commercially (Gilead, Lot 7530298).

[0468] Preparation of hRS7-Deruxtecan ADC

[0469] Preparation of hRS7-Deruxtecan ADC (hRS7-MC-GGFG-NH-CH2-Dxd)

[0470] hRS7-Deruxtean was prepared using 0.25 mL of reduced hRS7 antibody obtained from the above experiments. Deruxtean is a linker-toxin composed of a DX-8591 derivative (DXd) and a maleimide-GGFG peptide linker, purchased from BroadPharm (Cat No BP-29531, Lot 20230119J, San Diego, CA). 2.1 mg of the linker-toxin was dissolved in 0.20 mL of DMF to prepare a 10 mM solution. The concentration was determined to be 8.27 mM by RP-HPLC. 20.1 μL of this linker-toxin solution was added to 0.25 mL of reduced hRS7 solution to achieve a molar ratio of linker-toxin to hRS7 antibody of 10:1. The tube was placed in a refrigerator overnight for a total reaction time of 17 hours. The sample was then purified by buffer displacement using a VivaSpin 500 concentrator with an MWCO of 50 k.

[0471] Physicochemical characterization: The final ADC protein concentration was determined to be 5.06 mg / mL at 280 nm using a NanoDrop One spectrophotometer, with a total volume of 0.3 mL. The DAR was 7.53 as measured by RP-HPLC, indicating a yield of 62%.

[0472] Example 3: In vitro evaluation of the stability of antibody-drug conjugates (ADCs)

[0473] In vitro ADC stability test:

[0474] Each of the above ADC solutions was added to 1×PBS solution and mixed thoroughly to achieve a final ADC concentration in the range of 1-2 mg / mL. The tubes were then placed in a 37 °C water bath, with 50 μL samples taken periodically. The samples were kept at -20 °C until analysis. To measure accurate stability changes, including DAR changes in ADC molecules, an RP-HPLC method was developed. This method utilizes the property that high concentrations of salt can precipitate ADCs, thus it can be used to purify ADC plasma or serum samples. Using this RP-HPLC method, only the light chain containing one toxin and the heavy chain containing three toxins were used for stability determination, although other potential ADC substances (heavy chains containing one or two toxins) may be present. Briefly, after thawing the stability samples, ammonium sulfate solution (22.5 μL, 4M) was added to each sample and vortexed thoroughly. The tubes were centrifuged at 10,000 rpm for 2 minutes, and the supernatant was carefully removed. Add a diluted ammonium sulfate solution (50 μL, a mixture of 2.25 mL 4 M ammonium sulfate and 5.0 mL 10 mM pH 5.0 acetate buffer) to the tube. Shake well and centrifuge again. Discard the top aqueous phase and redissolve the precipitate in freshly added 50 μL of 10 mM pH 5.0 acetate buffer. Then analyze the sample using RP-HPLC.

[0475] Although MC-VCP-Exa forms a precipitate in PBS, surprisingly, hRS7 ADC (hRS7-MC-VCP-Exa) does not form a precipitate and is soluble.

[0476] Example 4: In vitro cytotoxicity

[0477] The potency of linker-toxin and antibody-drug conjugates was analyzed in vitro using a cell-based assay. In short, cancer cells expressing the target antigen were adhered to a detection plate, and then serially diluted antibody-drug conjugates were added to the plate and incubated for 3–5 days. After incubation, a solution of resazurine sodium (from ThermoScientific, Cat. No. B2118706, Lot N21I030) was added to the wells, and the signal intensity was measured. For each antibody-drug conjugate, the IC50 value and maximum cell killing rate were calculated.

[0478] All antibody-drug conjugates and linker-toxins were tested for in vitro cytotoxicity using the standard experimental methods described above. NCI-87 cells (from ATCC, Cat No. CRL-5822, Lot 70033475) were used as an exemplary cell line in this experiment. Additionally, clinically available Trodelvy® and antibody-drug conjugates prepared by linking hRS7 to the known linker-toxin deruxtecan (hRS7-Deruxtecan) were tested as controls. The results are shown in Table 3.

[0479] Table 3. Cytotoxicity of eczema and antibody-drug conjugates

[0480]

[0481] Table 3 shows that eczema mesylate exhibits strong cytotoxicity against the NCI-N87 cancer cell line. hRS7-MC-VCP-Exa also showed strong cytotoxicity, with an IC50 value of 0.314 mM, even superior to Trodelvy® and hRS7-Deruxtecan.

[0482] Example 5: Evaluation of the in vivo antitumor effect of antibody-drug conjugates

[0483] Tumor growth inhibition study in mice: Six- to seven-week-old female athymic nude mice (Foxn1nu) were obtained from Envigo RMS LLC (Indianapolis, IN) or other locations. After one week of acclimatization, cancer cells were subcutaneously instilled in 50% Matrigel suspension. Tumor growth inhibition was achieved when the tumor size reached 100-200 mm. 3 Mice were randomly divided into groups of five, and each group was intravenously injected with saline, glucose solution, or different doses of antibody-drug conjugates. Tumor volume was measured twice a week after drug injection. Relative tumor volume (RTV) was calculated using the following formula: RTV = TVn / TV0, where TVn is the tumor volume on day n and TV0 is the tumor volume on day 0; Tumor growth inhibition rate (TGI) was calculated using the formula: TGI (%) = (1 - T / C) × 100, where the T / C value was calculated using T / C = (mean RTV of treatment group) / (mean RTV of control group).

[0484] In vivo antitumor efficacy test in a mouse MDA-MB-468 cancer cell tumor model

[0485] In another study on antitumor efficacy, the human breast cancer cell line MDA-MB-468 was used. Following the methods used in previous studies, the cells were cultured and subcutaneously transplanted into the right side of each female nude mouse. Tumors were cultured until they reached a size of 100-200 mm.3 At that time, the test drugs were randomly divided into groups and administered via tail vein injection as described above, with a 5% glucose solution group serving as the control group. All test drugs were diluted with 5% glucose solution to 1 mg / mL or 2 mg / mL, sterilely filtered, and then placed into pre-sterilized and depyrogenated vials. All test drugs were administered on day 0 and again on day 7, at a dose of 10 mg / kg.

[0486] The results are as follows Figure 1A As shown, in the hRS7-MC-VCP-Exa treatment group, the tumor growth inhibition rate (TGI) reached >99% on and after day 30. Surprisingly, at the same dose, the antitumor effect of the hRS7-MC-VCP-Exa treatment group was far superior to that of the Trodelvy® treatment group.

[0487] In addition, such as Figure 1B As shown, these mice maintained normal weight gain and did not exhibit significant toxic reactions.

[0488] In vivo antitumor efficacy test in a mouse HCC1806 cancer cell tumor model

[0489] In another study on antitumor efficacy, the human breast cancer cell line HCC 1806 was used. This cell line exhibits moderate levels of Trop2 expression on its cell surface. Cells were cultured and subcutaneously transplanted into the right side of each female nude mouse. When the tumor size reached 100-200 mm... 3 At that time, the subjects were randomly assigned to groups and administered the test drug via tail vein injection as described above. A saline group was set up as a control group. All test drugs were diluted with 5% glucose solution to 1 mg / mL, 2 mg / mL, or 4 mg / mL, then sterilely filtered and placed into pre-sterilized and pyrogen-free vials. Each test drug was administered once on day 0 and once on day 7, at a dose of 10 mg / kg.

[0490] The results are as follows Figure 2A As shown, at a dose level of 10 mg / kg, hRS7-MC-VCP-Exa shrank tumors to almost unmeasurable levels after 10 days, and the antitumor effect persisted throughout the study. Compared to Trodelvy®, which only showed moderate antitumor activity against HCC1806 cancer cells, hRS7-MC-VCP-Exa again demonstrated significantly stronger antitumor activity.

[0491] In addition, such as Figure 2B As shown, these mice maintained normal weight gain and did not exhibit significant toxic reactions.

Claims

1. An antibody-drug conjugate comprising an anti-TROP2 antibody and an antitumor compound linked by a linker, wherein the linker and the antitumor compound are represented by the general formula -Q-L1-L2-(NH-Exa), wherein, Q represents -(succinimid-3-yl-N)-(CH2)5-C(=0)-, wherein -(succinimid-3-yl-N)- is a group represented by the following structure: , which is attached to the antibody at position 3 and is attached to the methylene group at the nitrogen atom at position 1, L1 is a dipeptide having the structure -Val-Cit- L2 is -NH-phenyl-CH2-O-C(=0)-, having the following structure: , -(NH-Exa) is a group represented by the following structure: 。 2. The antibody-drug conjugate of claim 1, wherein the linker and the antitumor compound have the following structure -(succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=0)-Val-Cit-NH-phenyl-CH2-O-C(=0)-(NH-Exa), wherein, -(succinimid-3-yl-N)- is a group represented by the following structure: which is attached to the antibody at position 3 and is attached to the methylene group at the nitrogen atom at position 1, -(NH-Exa) is a group represented by the following structure: wherein the nitrogen atom of the amino group at position 1 is the attachment position, and -NH-phenyl-CH2-O-C(=0)- represents the following structure: 。 3. The antibody-drug conjugate of claim 1, wherein the anti-TROP2 antibody is selected from Sacituzumab or Datopotamab.

4. The antibody-drug conjugate of claim 2, wherein the anti-TROP2 antibody comprises: V H , the V H comprises: a HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and V L , the V L comprises: a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO:

6.

5. The antibody-drug conjugate of claim 3, wherein the anti-TROP2 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 7; and a VL comprising the amino acid sequence of SEQ ID NO: 8 or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:

8.

6. A pharmaceutical composition comprising the antibody-drug conjugate of any one of claims 1-5, or a salt form thereof, as an active ingredient, and a pharmaceutically acceptable formulation component.

7. A method of treating cancer in an individual, comprising administering to the individual the antibody-drug conjugate of any one of claims 1-5, or the pharmaceutical composition of claim 6.

8. The method of claim 7, wherein the cancer is lung cancer, renal cancer, urothelial cancer, colorectal cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastric cancer, cervical cancer, head and neck cancer, or esophageal cancer.

Citation Information

Patent Citations

  • Drug conjugates and uses thereof

    CN115429893A

  • Process for purifying antibody

    US20020164328A1

  • Antibody composition-producing cell

    US20030115614A1

  • Glycoprotein compositions

    US20030157108A1

  • Antibody composition which specifically binds to CD20

    US20040093621A1